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1. Introduction 
The present diploma thesis deals with the evaluation of the protective role of 
bilirubin in the organism. It was part of the FWF–Austrian Science Fund 
supported project “The physiological relevance of bile pigments. In vitro and in 
vivo evidence of antioxidant, anti-mutagenic and anti-carcinogenic potential and 
their mechanism of action”. The study was carried out at the Department of 
Nutritional Sciences in Vienna, Emerging Field Oxidative Stress and DNA 
Stability. 
Yellow coloured bilirubin is an endogenous compound which is mainly derived 
from the degradation of red blood cells. The organism produces daily 
approximately 300 mg (0.7 mg/kg) of unconjugated bilirubin (UCB).  
For a long time bilirubin was considered as a waste product of heme catabolism 
or even associated with illness or toxicity (eg. newborn jaundice).  
Today there is mounting evidence indicating that bilirubin is more than a toxic 
waste product. It was shown that bilirubin has strong antioxidant and anti-
mutagenic properties. Furthermore it was found that individuals with Gilbert’s 
syndrome (GS) have markedly improved protection against oxidative stress and 
lower incidence of diseases such as cardiovascular disease. GS is a mild, 
hereditary unconjugated hyperbilirubinemia (> 17µmol/L), occurring in 
approximately 3-17% of the population. Molecular genetic background of 
Gilbert’s syndrome is a polymorphism in the gene promoter for hepatic uridine 
diphophate glucuronosyltransferase (UGT 1A1) which is responsible for 
regulation of bilirubin concentration in the body. The activity of UGT 1A1 is 
characteristically reduced in GS. 
The organism is constantly exposed to free radicals which in excess can lead to 
oxidative stress and cause deleterious damage to important biomolecules such 
as DNA. Increased DNA damage or insufficient repair is a risk factor for several 
diseases such as cardiovascular diseases, diabetes and cancer. Therefore 
2 
 
research is focused to investigate the possible role of exogenous and 
endogenous antioxidants in prevention of disease.  
Starting from this point, the present case-control study aimed at analysing the 
protective effect of mild elevated bilirubin towards oxidative stress and DNA 
damage in GS (n = 45) and a matched control group (n = 39). A further aim was 
to explore whether bilirubin possesses principle antigenotoxic functions.   
DNA damage was analysed in peripheral mononucleated cells (PBMCs) ex vivo 
using the Comet assay; a widely used method to detect different DNA damage 
end points. 
Due to the mild elevated bilirubin levels in GS the hypothesis was that the GS 
group would have improved resistance to DNA damage compared to the 
matched control group. 
So far, there is no existing literature that prooved the effect of elevated bilirubin 
concentrations in GS with the comet assay. Hence this thesis demonstrates 
results on this background for the first time.  
Lab work, data collection and literature research were done in collaboration with 
my colleague Barbara Rittmannsberger. Thus the parts “Literature survey” and 
“Materials and Methods “ are similar in both works. 
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2. Literature Survey 
2.1. Oxidative stress  
2.1.1. Free radicals 
Free radicals are molecules or fragments of molecules, which are characterised 
by a high reactivity and instability. The reactivity of free radicals is caused by 
unpaired electrons in the outer shell, which is not a desirable state for the 
molecule [VALKO et al., 2006]. In order to regain stability, free radicals deprive 
the missing electron randomly from other molecules.  
The most important class of free radicals in the biological system are radicals 
derived from oxygen, so called reactive oxygen species (ROS) and radicals 
derived from nitrogen, reactive nitrogen species (RNS) [DRÖGE, 2002]. 
Reactive oxygen species include radicals like the highly reactive hydroxyl 
radical (OH*-), superoxide radical (O2*-) and the non-radical hydrogen peroxide 
(H2O2), which is easily converted into a free radical [EVANS et al., 2004]. 
Reactive oxygen species in living organisms play dual roles, deleterious at high 
concentrations and sometimes beneficial roles only at low or moderate 
concentration. Beneficial physiological functions of reactive oxygen species are 
the defence against pathogens (eg. Phagocytosis), second messenger in a 
number of signalling pathways or the induction of mitogen response. Many 
responses mediated by ROS protect cells from oxidative stress. At high 
concentration ROS can cause damage to important cell structures, including 
lipids and membranes, proteins and DNA (deoxyribonucleic acid) by attacking 
them, comprising their natural function [VALKO et al., 2006]. 
The sources of ROS are either of endogenous or exogenous origin:  
Endogenous factors are by-products of normal cell metabolism. ROS can be 
released from the mitochondria during oxidative phosphorylation. During 
oxidative phosphorylation, approximately 1-3% of electrons leak to oxygen 
forming the superoxide radical O2*- (O2 + e---> O2*-) [VALKO et al., 2006]. ROS 
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are moreover released from peroxisomes during degradation of fatty acids or 
from leukocytes during the defence mechanism against microbes by 
“respiratory burst” [VALKO et al., 2006; WU et al., 2004]. 
Exogenous sources for ROS production are life style factors like diet, alcohol, 
cigarette smoking, exercise and environmental factors like exposure to toxins 
and radiation [GIDRON et al., 2006].  
 
2.1.2. Free radicals and Oxidative stress  
As mentioned before, free radicals are not always deleterious at low or 
moderate concentrations. In healthy individuals, there is almost a balance 
maintained between oxidants and antioxidants [VALKO et al., 2006].  
If the balance between oxidants and antioxidants is disturbed by excessive 
ROS production or deficient capacity of the antioxidant system, an undesirable 
state occurs that is termed “oxidative stress” [COLLINS, 2009]. See Figure 1 
 
Figure 1: Oxidative Stress (modified after ELMADFA and LEITZMANN, 2004) 
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During oxidative stress in vivo ROS can attack important biomolecules. Cellular 
targets for oxidative modification include DNA, lipids and proteins. Which 
biomolecule is modified depends on several factors such as location of ROS 
production, relative ability for the biomolecule to be oxidised and availability of 
metal ions [EVANS et al., 2004]. 
Antioxidants can prevent or delay the oxidation of oxidisable substrates in vivo 
by detoxification of free radicals. This works by donation of hydrogen atom 
(electron) forming a stable compound and antioxidant-derived radical               
(X* + IH   XH + I*) [NIKI, 2010]. Antioxidants are of physiological 
relevance and can either be enzymatic or non-enzymatic. Enzymatic antioxidant 
systems are, for example, the superoxide dismutase (SOD), catalase (CAT) or 
glutathione peroxidise (GSH-Px). Non enzymatic antioxidants can be, for 
example, vitamin E, vitamin C, carotinoids and serum proteins like uric acid and 
bilirubin. Some of these antioxidants are synthesised in the body, like 
glutathione, uric acid and bilirubin but some have to be provided alimentary, like 
vitamin C, E and β-carotin [ELMADFA and LEITZMANN 2004]. 
 
2.1.3. Oxidative stress and DNA damage 
The DNA (deoxyribonucleic acid) is a relatively fragile biomolecule, which stores 
genetic instructions in living organisms. The DNA structure consists of two 
connected polymers which are made of simple units called nucleotides. Each 
nucleotide is composed of three parts: a phosphate, a sugar (deoxyribose) and 
a nitrogen base. Sugar phosphates link together by ester bonds forming the 
backbone of the double helix. The nitrogen bases pyrimidines (cytosine and 
thymine) and purines (adenine and guanine) bond with one another according 
to very strict rules (complementary base pairing) whereby the two single-strands 
are connected. Hence adenine pairs with thymine (AT) and guanine pairs with 
cytosine (GC) [SILVERSTEIN et al., 2008]. See Figure 2 
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Figure 2: The basic structure of DNA [GHR, 2009] 
The most important derivate of ROS, which causes damage to DNA is the 
hydroxyl radical (OH*-). OH*- reacts closely to its site of formation and 
demonstrates the most reactive form of ROS which can react with all 
components of the DNA including purines, pyrimidines and DNA backbone 
[VALKO 2006]. In the body the OH*- radical can be derived from H2O2. The 
H2O2 molecule is less reactive and more stable compared to other ROS. 
However it plays an important role in oxidative damage since it easily diffuses 
through biological membranes reaching other cellular compartments and 
producing further cellular injury [MAYNARD et al., 2009]. At normal state H2O2 
is converted into water and molecular oxygen by the action of antioxidant 
enzymes like glutathione peroxidase, superoxide dismutase (SOD) or catalase 
(CAT). If transition metals such as copper [Cu] or iron [Fe] are present, H2O2 
can be reduced to the highly reactive OH*- via the Fenton’s reaction Fe2+ + 
H2O2 Fe3+ + OH. + OH− [REUTER et al., 2010]. See Figure 3 
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Figure 3: Generation and detoxification of ROS [ROBERTS and SINDHU, 2009] 
The genome is under continuous attack from a variety of DNA–damaging 
agents leading to many different types of DNA lesions. To date, more than 
100 oxidised DNA products have been identified [VALKO et al., 2006]. 
Damaged products of DNA include single-strand breaks (SSB), double-strand 
breaks (DSB), base-less sugar or AP (apurinic/apyrimidinic) sites, DNA-Protein 
cross links and modified bases. DNA bases can be modified by oxidation or 
reduction, alkylation and deamination [EVANS et al., 2004; MAYNARD et al., 
2009]. 
DNA damage can be devastating to the normal physiology leading to mutation 
and/or cell death. In order to avoid accumulation of DNA damage and its 
deleterious effect, damage needs to be repaired efficiently. The major repair 
pathways in mammalian cells are base excision repair (BER), nucleotide 
excision repair (NER), DSB repair and mismatch repair (MMR). BER is the 
predominant pathway for repair of ROS- generated lesions. NER removes bulky 
helix-distorting DNA lesions. In case of damage where both strands of the DNA 
are affected, DSB repair is used [MAYNARD et al., 2009]. 
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2.2. Methods for measuring DNA damage 
For detecting different endpoints of DNA damage a couple of methods exist. 
Comet assay is used to measure strand breaks and alkali labile sites (AP–
sites). The inclusion of lesion-specific enzymes allows more specific and 
sensitive investigations of oxidative stress induced DNA damage. 8-OxodG is 
one of the major products of DNA oxidation and thus an important biomarker for 
oxidative stress induced DNA damage. 8-OxodG can be measured by various 
different methods like HPLC –ECD, GC/ MS, LC-MS/MS [COLLINS, 2009].  
 
2.2.1. Oxidised Purines (8-OxodG) 
Among the DNA bases purine and pyrimidine, guanine is most prone to 
oxidation. Throughout the oxidation of guanine, a hydroxyl radical is attached to 
the heterocyclic structure of guanine at the 8th position (C8-OH-adduct radical) 
and releases an H-Atom forming the oxidat ion product 8-OxodG (8-Oxo-7,8-
dihydro-2’-deoxyguanosine) [WAGNER und JAHREIS, 2004]. The existing keto-
enol tautomerism between the endproducts 8-OxodG and 8-OHdG (8-hydroxy-
2’-deoxyguanosine) favours the 8-OxodG product (see Figure 4) 
[VALAVANIDIS et al., 2009]. 
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Figure 4: Forming 8-OxodG after reaction of 2´-desoxyguanosine with hydroxyl radicals 
[VALAVANIDIS et al., 2009] 
8-OxodG is one of the most important lesions of DNA caused by free radicals. 
Therefore, 8-OxodG is often used as a biomarker for oxidative stress and it is 
also considered as a risk factor for oxidative stress related diseases such as 
cancer, atherosclerosis and diabetes [WU et al., 2004]. 
The lesion of 8-OxodG is particularly harmful, because it is able to structurally 
mimic thymine base and thus able to bypass replicative DNA polymerase which 
removes damaged bases before DNA replication. If 8-oxodG is not fully 
removed before replication, wrong base pairing occurs. Generally, adenine 
pairs with thymine and guanine pairs with cytosine, but due to oxidative 
modification of guanine, it pairs mistakenly with Adenine leading to guanine-
thymine-transversion (GT-transversion mutation) [DAVID et al., 2007]. 
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8-OxodG was first detected by Kasai and Nishimura in 1984 with high 
performance liquid chromatography (HPLC) and electron capture detector 
(ECD). Consecutively different methods for measuring 8-OxodG were 
developed [WAGNER and JAHREIS, 2004]. 
 
 HPLC-ECD (high pressure liquid chromatography-electron capture detector) 
A very sensitive (detection limit: 2 – 10 fmol) and correct method that has 
low costs of equipment and is commonly used. A disadvantage of this 
method is that it can only detect electrochemical active matters (like 8-
OxodG) [WAGNER and JAHREIS, 2004] and suffers from adventitious 
oxidation during sample preparation [COLLINS, 2009; ESCODD, 2003]. 
 
 GC/MS (gas chromatography/mass spectrometry) 
With gas chromatography and mass spectrometry most of the oxidised 
modifications are detectable (detection limit: 18 fmol). But to mention also 
some disadvantages it is a more expensive method and derivatisation is 
necessary. The obtained 8-OxodG levels are artificially increased what 
makes the interpretation of the results more complicated [WAGNER and 
JAHREIS, 2004]. 
Gas chromatography is therefore a not really suitable method to measure 
basal 8-OxodG in biological material [COLLINS, 2009]. 
 
 LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry) 
Liquid chromatography is theoretically the most powerful method with a 
detection limit of 7.5 – 10 fmol in contrast it is a very expensive method 
[WAGNER and JAHREIS, 2004]. But this method is also considered as 
relatively simple and sample pre-treatment is not absolutely necessary. LC-
MS/MS method is often preferred because of its specificity and high 
sensitivity [LEE et al., 2010]. It is a method that can measure more than one 
product from DNA oxidation and is therefore often used for quantitative 
analysis of the oxidised nucleosides [HENRIKSEN et al., 2009].  
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2.2.2. Single cell gel electrophoresis (SCGE) (Comet Assay) 
The Comet Assay, also called single cell gel electrophoresis (SCGE), was first 
carried out under neutral conditions by Östling and Johanson in 1984. The 
SCGE under neutral conditions was only for analysing double strand breaks. 
Therefore, a few years later in 1988 Singh et al. described a similar method but 
using alkaline conditions and a sensitive method for measuring both, single- 
and double-strand breaks in DNA, was found [DHAWAN et al., 2009]. 
The Comet Assay is named after the receiving image, which occurs after 
staining and looks like a “Comet”. The head of a Comet contains intact DNA 
whereas the tail is built by damaged or broken pieces of DNA [PIPERAKIS, 
2009]. 
The advantages of the Comet Assay include  
 the high sensitivity for detecting low levels of DNA damage,  
 the small sample size (from 10000 to 50000 cells),  
 the flexibility to use proliferating as well as non-proliferating cells, 
 low costs, 
 the easy and fast application, 
 that results can be obtained on the same day,  
 that fresh and frozen samples are suitable and 
 virtually any eukaryotic cell population can be analysed. [DHAWAN et 
al., 2009; PIPERAKIS, 2009] 
Some limitations and disadvantages of the Comet Assay might be  
 that also non-oxidised DNA-damage is detectable, 
 reproducibility is low, [WAGNER and JAHREIS, 2004] 
 aneugenic effects (that are maybe a possible mechanism for 
carcinogenicity) and epigenetic mechanisms of DNA damage are not 
detected, 
 single cell data (which may be rate limiting), 
 small cell sample (leading to sample bias) and 
 technical variability. [DHAWAN et al., 2009] 
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Although the Comet Assay may be less precise than for example HPLC the 
advantages of the Comet Assay predominate the disadvantages and the SCGE 
has been widely used in the last years in many different fields of research. By 
using this assay, it was possible to analyse the impact of oxidative stress in 
human diseases, to detect effects of environmental exposure to genotoxins and 
also to clarify the importance of antioxidants in our nutrition [COLLINS, 2009]. 
 
Procedure of the Comet assay: 
The key principle of the method is the migration of the damaged DNA in an 
electric field at alkalised pit and measures the different intensities of the formed 
“comets” (see Figure 5). 
For the procedure in the single cell gel electrophoresis cells (for example 
isolated peripheral human lymphocytes) are placed on a microscope slide with 
agarose. They have to be lysed with detergent of high salt to form nucleoids, 
which contain non-nucleosomal but still supercoiled DNA. Cells are exposed to 
an electric field in the electrophoresis and fragments of DNA can then migrate 
toward the anode and forming a “comet tail”. The amount of DNA in the tail 
represents the frequency of strand breaks and the comet assay is therefore a 
method for measuring DNA damage [COLLINS et al., 1997]. 
DNA strand breaks are then visualized with fluorescence microscopy after 
staining with a DNA-binding dye, such as ethidium bromide. Ethidium bromide 
is more efficient for double strand breaks than for single strand breaks 
[COLLINS, 2004]. 
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Figure 5: Photomicrographs of DNA from human lymphocytes after electrophoresis (left: no 
“comet”: no DNA migration; right: “comet”: damaged DNA, after treatment with ENDOIII) 
A common additional step in the comet assay procedure is the treatment of 
cells with H2O2. After incubation of cells with H2O2 mainly DNA strand breaks 
occur but also some oxidation in bases can occur. The receiving amount of 
DNA breaks is then characteristic for the changes in the resistance of the cells 
towards exogenous oxidative DNA damage [COLLINS, 2009]. 
 
2.2.3. Modified version of the Comet Assay 
The comet assay under standard alkaline conditions (pH ≥ 13) detects strand 
breaks (SSB and DSB) and alkali labile sites (AP-sites). AP-sites are locations 
on the DNA without DNA base. AP-sites occur as intermediates during DNA 
repair or arise spontaneously due to chemical change in bases or sugars. The 
detection of strand breaks and AP-sites therefore is not a specific index for 
oxidative stress in the organism [COLLINS, 2004; COLLINS et al., 2008]. 
In contrary to DNA strand breaks or AP-sites, oxidised bases are specific 
indicators of oxidative damage, reflecting the background damage caused by 
ROS in the cells. The value of oxidised bases can be detected with comet 
assay, by inclusion of lesion-specific enzymes after lysis. Hence, two particular 
DNA repair enzymes are frequently included; Endonuclease III (ENDO III) for 
detection of oxidised pyrimidines and formaminopyrimidine DNA glycosylase 
(FPG) which detects damaged purines including the major oxidation product of 
DNA damage 8 oxodG but also ring-opened purines or formamidopyrimidines 
(Fapy) [COLLINS 2004; COLLINS et al., 2008]. 
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The enzymes recognise and remove the damaged base by glycosylase activity 
generating an AP-site. Subsequently associated AP-lyase cleaves the 
phosphodiester backbone at AP-site sites creating a nick in the DNA (See 
Figure 6). During the comet assay procedure strand breaks cause supercoiling 
of DNA to relax. Subsequently broken pieces of DNA migrate towards the 
anode during electrophoresis under alkaline conditions forming a typical comet 
tail whereas intact parts of DNA remain in the head [COLLINS, 2004; COLLINS 
et al., 2008]. 
 
Figure 6: Function of FPG and ENDO III 
In parallel with enzyme incubation, an extra slide is incubated with enzyme 
buffer alone serving as a control slide. The score from this slide is subsequently 
subtracted from the enzyme score to receive the net enzymatic sites. Most likely 
alkali labile sites (AP) are fully detected on the control slide. Therefore, net 
enzyme give precise and specific information about levels oxidised bases in the 
body [COLLINS, 2004; COLLINS et al., 2008]. 
The modified version of the comet assay is often used in order to investigate the 
relation between antioxidant levels in plasma and DNA damage or to attain 
changes DNA damage profile after supplementation with selected antioxidant-
rich foods in human intervention trials [COLLINS, 2009]. Furthermore the 
modified version of comet assay is used to test the genotoxic potential of 
substances. 
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Figure 7: Methodology of modified version of comet assay. Detection of oxidised bases by 
inclusion of the bacterial lesion-specific enzymes FPG and ENDO III [modified after DUTHIE, 1999] 
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2.3. Bile pigments 
2.3.1. Bilirubin structure 
Bile pigments including yellow bilirubin and green biliverdin are natural 
endogenous compounds derived from catabolism of heme. Both molecules 
belong to the family of tetrapyrrolic compounds [VITEK and OSTROW 2009]. 
The fundamental structure of bilirubin composes four covalent connected 
pyrrole rings, forming an open, linear, tetrapyrrolic chain. The two outer pyrrole 
rings carry a polar lactam (-CO-NH) group and the central pyrrole rings carry a 
polar propione sidechain (-COOH) (see Figure 8) [VITEK and OSTROW 2009]. 
Bilirubin and biliverdin are flexible molecules, which can assume different 
molecular conformations. Bilirubin preferable has a folded ridge tile 
conformation, which is caused by the formation of intermolecular hydrogen 
bonding between carboxyl group and other polar groups in the molecule. This 
constellation is responsible for the lipophilic character of bilirubin at 
physiological pH, as the polar groups are in a way ‘neutralised’ [MC DONAGH 
2010a]. In addition to its lipophilic character, bilirubin is susceptible to oxidation 
and very sensitive towards light; therefore investigations of bilirubin require 
minimal exposure to oxygen and light [VITEK and OSTROW 2009]. 
17 
 
 
Figure 8: Two- and three-dimensional structures of (1) bilirubin and (2) biliverdin [BULMER et al., 
2008b] 
 
2.3.2. Heme Metabolism 
Heme is well known as a component of hemoglobin in red blood cells. 
Furthermore a wide range of enzymes like cytochrome P450, catalase and 
peroxidase contain heme as a prosthetic group, which is released during their 
turnover [SEDLAK and SNYDER 2004]. 
Red blood cells have a limited life span and are decomposed in the 
reticuloendothelial system after 120 days whereby heme is released. Each day, 
approximately 300 mg (0.7 mg/kg) of unconjugated bilirubin (UCB) are 
produced which equates the amount of destructed heme in the body. 75 % of 
de novo UCB is derived by the destruction of senescent red blood cells and the 
remaining 25 % are derived from non-hemoglobin heme proteins [VITEK and 
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OSTROW 2009]. UCB is efficiently metabolised in the intestine by the action of 
anaerobic bacteria. The products of bacterial metabolism, so called urobilinoids, 
like stercobilin are mainly eliminated in the stool – excretion of yellow-orange 
coloured stercobilin 40-280 mg/d. Small proportions of urobilinoids undergo 
enterohepatic circulation, where a small part reaches the kidney and is excreted 
in the urine in the form of urobilin or urobilinogen approximately 0.64 mg/24h 
urine. In the case of high heme decomposition or liver damage the excretion of 
urobilin or urobilinogen in the urine is increased [PETRIDES, 2007]. 
 
The breakdown of heme is a multistep process and involves the two major 
enzymes, microsomal heme oxygenase (HO) and cystolic biliverdin reductase 
(BVR) (see Figure 9) [VITEK and OSTROW 2009]. Two genetic isoforms of 
heme oxygenase have been identified: HO-1 and HO-2. HO -1 is mainly 
expressed in reticuloendothelial cells and belongs to the family of heat shock 
proteins. HO-1 can be induced by stimuli which provoke oxidative stress (free 
oxygen radicals, free heme, heavy metals, bacterial lipopolysaccharides, 
hydrogen peroxide and ultraviolet light) whereas HO-2 is constitutive [VITEK 
and OSTROW 2009]. Bilirubin can be locally and temporally increased by 
specific induction of HO-1 in order to resist various situations of oxidative stress 
in short- and long-term [TOMARO and BATTLE 2002].  
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Figure 9: Metabolism of heme [BULMER et al., 2008b] 
The first step of heme cleavage which is also the rate limiting step is mediated 
by HO Heme oxygenase which uses NADPH as a cofactor and oxidatively 
cleaves the heme ring at the α-carbon-bridge, forming the direct precursor of 
bilirubin, green coloured biliverdin (BV), carbonmonoxid (CO) and Iron (Fe2+). 
Fe2+ can be reused and biliverdin is quickly reduced by biliverdin-reductase and 
NADPH to unconjugated bilirubin (UCB) [VITEK and OSTROW, 2009]. 
Biliverdin is only a transient intermediate. It is entirely and quickly reduced by 
biliverdin reductase to UCB. BVR occurs as a complex with membrane bound 
HO and in the cytosol facilitating the quick reduction of biliverdin [MC DONAGH, 
2010a]. 
Colourfully the metabolism of bilirubin is displayed during bruising, where blue-
red stained heme is followed by blue-green colour of biliverdin and by yellow 
colouration of bilirubin. Conjugated systems of double-bondings cause the 
colouration of these porphyrin molecules [KOOLMAN and RÖHM, 2002; 
BULMER et al., 2008b]. 
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2.3.3. Bilirubin transport and excretion 
Unconjugated bilirubin that is referred to as “indirect bilirubin” is poorly soluble 
in water. UCB needs to be tightly bound to serum albumin in order to be 
transported to the liver via the systemic blood circulation.  
Before entering the liver, bilirubin is dissociated from its carrier protein, albumin, 
and taken up by the hepatocyte across the sinusoidal membrane. In the cytosol 
of hepatocytes bilirubin binds to ligandin with high affinity and is transported to 
the endoplasmatic reticulum (ER), where unconjugated bilirubin is converted 
into its water soluble form “direct bilirubin” by conjugation. Bilirubin is 
conjugated with glucuronic acid or sugar molecules (xylose or glucose) by UDP 
glucuronosyl transferase (UGT1A1) forming bilirubin monoglucuronide and 
diglucuronides [KAMISAKO, 2000; MC DONAGH, 2010a]. If this enzyme is not 
working properly, it can lead to an increase in bilirubin levels and bilirubin 
associated metabolic conditions like Gilbert’s syndrome, crigler-najjar syndrome 
or neonatal hyperbilirubinemia (See also chapter 2.4.) [PETRIDES, 2007]. 
The water soluble glucuronide derivates are excreted into the bile by the 
canicular ATP-dependent transport protein MRP2 (multidrug resistance 
associated protein 2) [MC DONAGH, 2010a].  
In the intestine, bilirubin mono and di-glucuronide are hydrolysed by the action 
of anaerobic bacteria (β-Glucuronidasen). Bilirubin is reduced stepwise to 
stercobilinogen, which is a colourless compound that is partly oxidised to 
yellow-orange coloured stercobilin. Most of the end products of bilirubin 
metabolism are excreted with the stool, a small part is reabsorbed and 
undergoes enterohepatic circulation [PETRIDES, 2007; KOOLMAN and RÖHM, 
2002]. 
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2.3.4. Physiological concentrations of bilirubin 
The physiological concentration of bilirubin in plasma is about 0.1 – 1.2 mg/dl 
(1.7 – 20.5 µmol/l) [PETRIDES, 2007]. Bilirubin levels vary significantly with 
gender, men in general show significantly higher serum bilirubin levels (0.72 
mg/dl) compared to women (0.52 mg/dl) [ZUCKER et al., 2004]. “Unconjugated 
Bilirubin”, which is tightly bound to serum album, demonstrates the principle bile 
pigment in mammals and accounts 90 % of total circulating bilirubin in the body 
and less than 0.01 % of total bilirubin is unbound (free bilirubin, Bf) [VITEK and 
OSTROW, 2009]. 
 
2.4. Hyperbilirubinemia 
As discussed before, bilirubin that is generated during the decomposition of 
erythrocytes is called unconjugated bilirubin. It is immediately bound to albumin 
in blood and transported to the liver. In the liver, unconjugated bilirubin is 
conjugated to glucuronic acid, consequently gets water soluble and is finally 
called conjugated bilirubin. A mutation in the gene promotor region of bilirubin-
uridine-diphosphate-glucuronyl transferase (UGT1A1) can cause 
hyperbilirubinemia [THOMPSON, 2003]. 
Hyperbilirubinemia is a benign or malign condition that is caused by elevated 
bilirubin levels.  
Mild rises in bilirubin levels can be caused by:  
 Gilbert’s syndrome:  >17.1 µmol/l unconjugated bilirubin [BULMER et al., 
2008a] 
 Rotor syndrome: increased (51.3 - 171 mg/dl) levels of conjugated bilirubin 
[MAIER, 2000]     
Strong rises in bilirubin can be caused by: 
 Neonatal hyperbilirubinemia (jaundice): conjugated and unconjugated 
bilirubin levels can be increased [THOMPSON, 2003] 
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 Crigler-Najjar-Syndrome: >335 µmol/l unconjugated bilirubin [BULMER et 
al., 2008a] 
 Dubin-Johnson Syndrome: 51 – 257 µmol/l conjugated bilirubin [GARTUNG 
and MATERN, 1999] 
Bilirubin levels can also rise by haemolysis (increased breakdown of 
erythrocytes), hepatitis, choledocholithiasis, cirrhosis and chemotherapy 
[GARTUNG and MATERN, 1999]. 
 
2.4.1. Gilbert’s syndrome 
Gilbert’s syndrome (GS) is also called “Morbus-Meulengracht” or “Icterus 
intermittens juvenilis”. The clinical picture was first described by Gilbert and 
Lereboullet in 1901 and it is characterised by episodes of intermittent jaundice 
in the absence of haemolysis or liver disease [MUKHERJEE, 2011]. 
Gilbert’s syndrome is the most common hereditary cause of increased bilirubin 
and is found in up to 3 – 17 % of the population [BULMER et al., 2008a]. Men 
are four times more often affected than women [GARTUNG and MATERN, 
1999] and it is typically diagnosed for the first time during adolescence 
[KAPLAN et al., 2003]. 
Generally Gilbert’s syndrome is considered as harmless in adults, although an 
incidental finding of hyperbilirubinemia may raise the possibility of liver disease 
[BOSMA et al, 1995]. 
Genetically the syndrome is characterised by a hereditary mutation in the gene 
promoter for hepatic uridine diphosphate glucuronosyltransferase (UGT1A1) 
[BULMER et al., 2008a]. The polymorphism in the UGT 1A1 gene promoter is 
commonly an additional TA base in the TATAA box. Affected individuals have 7 
TA repeats, whereas non-affected individuals have 6 repeats. Due to the 
insertion of an additional TA base the activity of the UGT1A1 enzyme is 
decreased [KAPLAN et al., 2003]. As mentioned before, UGT1A1 is responsible 
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for glucuronidation of UCB and bilirubin clearance. In persons with GS a 30 % 
rest activity of the enzyme is found. Therefore, the circulating unconjugated 
bilirubin concentration is increased [BOSMA et al., 1995]. 
Bilirubin has an antioxidative potential in vitro [NEUZIL and STOCKER, 1994] 
and the ability to decrease oxidation of the plasma [FREI et al., 1988]. Results 
of a human study showed a better protection of serum oxidation in GS as for 
controls [BULMER et al., 2008a]. 
Elevated levels of serum bilirubin may play an important role in the prevention 
of ischemic heart disease. Due to the antioxidant capacity of bilirubin a possible 
protection of lipids and lipoproteins against oxidation is assumed. Therefore, 
elevated bilirubin levels, like in GS, might protect against atherosclerosis 
[YESILOVA et al., 2008]. 
Another study by Vitek at al. showed that high serum bilirubin levels are related 
to low urinary excretion of biopyrrins, an oxidative metabolite of bilirubin [VITEK 
et al., 2007]. Urinary excretion of biopyrrins is correlated with oxidative stress 
[SHIMOHARADA et al., 1998] and therefore, correlation with cardiovascular 
diseases (CVD) like heart failure [HOKAMAKI et al., 2004] or coronary spastic 
angina [MORITA et al., 2001]. These studies proved that people with GS are 
probably better protected against oxidative stress and CVD because of low 
urinary excretion of biopyrrins.  
Schwertner et al. also described that high serum total bilirubin levels decrease 
the risk of coronary artery diseases [SCHWERTNER et al., 1994]. The first 
study on cardiovascular heart disease (CHD) risk and especially Gilbert 
syndrome patients was carried out by Vitek et al. in 2002. In this study, results 
showed that only 2 % of people with GS were found to have CHD compared to 
12.1 % of the general population. First results concerning the decreased risk of 
CHD particularly in GS patients were shown [VITEK et al., 2002].  
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2.4.2. Neonatal hyperbilirubinemia 
Neonatal hyperbilirubinemia is leading to jaundice, which means the yellowing 
of the skin and other tissues of a newborn infant. Cause of neonatal jaundice is 
an imbalance between UCB production and elimination [AHLFONS et al., 2009]. 
High serum bilirubin concentrations can be found around 2 – 5 days after birth 
and the bilirubin levels normally don’t exceed a level of 90 µmol/l. In about 70 % 
of newborns this condition exists but bilirubin levels decline to a normal value 
after some days and therefore neonatal hyperbilirubinemia is mostly harmless 
[THOMPSON, 2003]. 
Normally jaundice in adults is harmless, but as the tissues protecting the brain 
are immature in newborns, neonatal jaundice can cause acute bilirubin 
encephalopathy (ABE) and this can lead to kernicterus or death. Consequences 
of kernicertus can be for instance athetoid cerebral palsy, auditory dysfunction, 
ocular movement disorders or dental enamel dyslasia. Phototherapy is a well-
established method for enhancing UCB elimination in order to prevent ABE and 
kernicterus [AHLFONS et al., 2009]. 
 
2.4.3. Crigler-Najjar-Syndrome (CNS) 
There are two syndromes of more severe unconjugated hyperbilirubinemia, 
namely the rare type 1, which often leads to neonatal death, and the more 
common and more harmless type 2. Both are caused by severe deficiency of 
the enzyme UGT1A1 [THOMPSON, 2003]. 
In type 1, the disease is autosomal recessive inherited with an incidence of 
1:10000 [GARTUNG and MATERN, 1999] and in neonates this can rapidly 
cause jaundice in the first days with an unconjugated bilirubin level from 350 to 
950 µmol/l. A correct treatment is necessary to avoid development of 
kernicterus or brain damage.  
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Crigler-Najjar-Syndrome type 1 desires a whole body blue-light phototherapy for 
16 h daily. Another rehabilitation would be plasmapheresis until a liver 
transplantation is possible, as a definitive cure. [THOMPSON, 2003] Another 
standard treatment for Crigler Najjar Syndrome would be the Phenobarbital 
therapy. As in many of these patients a defect of the production of the enzyme 
UGT1A1 occur, an addition of Phenobarbital can stimulate enzyme production 
and therefore, helps to remove bilirubin. However, not all patients respond 
positively to Phenobarbital therapy as a reduced enzyme production is not the 
only cause of illness [http://carmonet.50webs.com/CNS/phenobarb.html; access 
date: 16.06.2011]. 
Crigler-Najjar-Syndrome type 2 can either be inherited dominant with 
incomplete penetrance or autosomal recessive. On the contrast to type 1 
bilirubin levels are lower (<350 µmol/l) [THOMPSON, 2003] and the rest activity 
of the UGT1A1 can be <10 % compared to normal [GARTUNG and MATERN, 
1999]. Brain damage doesn’t occur and persistent mild jaundice is only noticed 
in childhood [THOMPSON, 2003].   
Drugs like penicillin or salicylates have to be avoided in people with Crigler-
Najjar-Syndrome, because they have the ability to displace unconjugated 
bilirubin from albumin [THOMPSON, 2003]. 
 
2.4.4. Dubin-Johnson Syndrome and Rotor Syndrome 
Dubin-Johnson and Rotor Syndrome are rare forms of non-haemolytic and 
autosomal recessive disorder with conjugated hyperbilirubinemia without 
cholestasis [THOMPSON, 2003]. 
In the Dubin-Johnson Syndrome bilirubin levels are between 51 – 257 µmol/l 
and usually it is asymptomatic but may be diagnosed by incidental finding in 
early infancy. Generally this syndrome is harmless but jaundice can occur 
sometimes during pregnancy or intake of hormonal contraceptives [GARTUNG 
and MATERN, 1999]. 
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A typical indication of Dubin-Johnsons Syndrome is an accumulation of black 
pigments in the liver hence, at laparoscopy the liver appears strikingly black. 
Another diagnostic finding is that the urinary coproporphyrin excretion is either 
increased or decreased [THOMPSON, 2003]. 
The Rotor-Syndrome is a disorder similar to the Dubin-Johnson Syndrome with 
unknown origin and unpigmented liver cells. The main symptom is a non-itching 
jaundice and elevated conjugated bilirubin serum levels [THOMPSON, 2003]. 
 
2.5. Protective role of bile pigments in literature 
2.5.1. First findings and bilirubin as antioxidant 
Throughout a long period, the best property attributed to bilirubin was its role as 
a waste product of heme catabolism that needed to be excreted from the body. 
Bilirubin at severe high concentrations can be neurotoxic causing acute or 
chronic neurological damage [BULMER et al., 2008b]. 
The first evidence that bilirubin is more than a toxic by-product, was delivered 
by Bernhard in the 1950s. In his experiment only small quantities of bilirubin 
stabilised Vitamin A or β-carotene and effectively protected lipids, especially 
linoleic acid from oxidation [BERNHARD et al., 1954]. 
Later on it was shown that bilirubin can inhibit lipidperoxidation due to a 
synergistic action with membrane bound Vitamin E [STOCKER and 
PETERHANS, 1989]. Unconjugated bilirubin was also shown to synergise with 
α-tocopherol to prevent lipoprotein lipid peroxidation. Furthermore, bilirubin 
inhibited the formation of cholesterylester hydroperoxide (CE-OOH), the 
oxidation product of LDL, by scavenging alpha tocopherol radical (TO) in LDL  
[NEUZIL and STOCKER, 1994]. 
In the last two decades the beneficial role of bile pigments gained high interest 
and much research was done in order to confirm their physiological importance.  
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It was demonstrated, that bilirubin has anti-mutagenic, anti-viral, anti-
inflammatory and anti-proliferative properties [BULMER, 2008; ZUCKER et al., 
2004]. 
More recent investigations showed that bilirubin and biliverdin have the ability to 
supress lipopolysaccharide (LPS) - induced oxidative burst in isolated human 
neutrophils [JANSEN et al., 2010].  
Sedlak and co-workers investigated the complementary effect of bilirubin and 
reduced glutathione (GSH) two prominent endogenous antioxidants. They 
indicated that lipophilic bilirubin protects mainly against lipid peroxidation of cell 
membranes, whereas GSH which is a hydrophilic compound, prevents the 
oxidation of water soluble proteins [SEDLAK et al., 2009]. 
It was suggested that nanomolar concentrations (10 nM) of BR can protect 
cultured cells from an excess of H2O2 [DORÉ et al., 1999]. 
The exact working mechanism of bilirubin as an antioxidant remains unclear 
and more research is needed in this area. One suggestion independent from 
the structural aspects of bilirubin is that the antioxidant action of bilirubin 
originates from the redox-recycling with biliverdin. Thus, when bilirubin acts as 
an antioxidant, bilirubin is oxidised to biliverdin, which is subsequently reduced 
back to bilirubin by BVR. This mechanism amplifies the antioxidant property of 
bilirubin as it is regenerated over and over again. Thus, enabling low 
concentrations of bilirubin to cope with high concentrations of reactive oxygen 
species [Mc DONAGH,  2010b]. This was chemically shown by incubation of 
bilirubin-albumin with 2,2’ –azobis (2-amidinopropane) hydrochloride (AAPH), 
where BV was formed during peroxyl –radical attack [BARANO et al., 2002]. 
The recycling between bilirubin and biliverdin seems to be a plausible 
explanation for the strong antioxidative potential of bilirubin. Nevertheless some 
researchers are very critical with this hypothesis. Maghzal and co- workers for 
instance could not confirm the hypothesis that oxidation of bilirubin specifically 
delivers biliverdin [MAGHZAL et al., 2009]. Moreover the in vitro experiments of 
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Jansen and co-workers speak against this theory. In their study, the conversion 
of BR to BV was less than 5% for all oxidants tested [JANSEN et al., 2010]. 
Stocker also implicates structural aspects of bilirubin. Bilirubin contains a 
system of conjugated double bonds and a pair of reactive hydrogen bonds. The 
latter can neutralize free radicals via H- donation [STOCKER, 2004]. 
 
2.5.2. Albumin-bound bilirubin 
A strong evidence exists that albumin bound bilirubin protects proteins against 
oxidative damage by several types of reactive oxygen and nitrogen species 
(RONS). Already in 1987, an in vitro study by Stocker et al. demonstrated that 
free fatty acids, especially linoleic acid, transported by albumin can be protected 
from oxidative damage. The albumin-bound bilirubin increases with specificity 
and reactivity against RONS and this result in an elevated protection of plasma 
proteins and lipids. In this in vitro study the antioxidative effect of bilirubin in 
plasma was also compared with uric acid and vitamin C. The results indicate 
that bilirubin has the same antioxidative effect as uric acid but has a weaker 
effect compared to vitamin C. But this was an in vitro study and still more 
investigations would be needed to demonstrate this theory [STOCKER et al., 
1987]. 
To sum up, there is of course already some evidence that proves the 
antioxidant capacity of bile pigments in vitro. In fact, however, it is necessary to 
observe whether this action remains also in vivo situations.  
There are only a few in vivo studies illustrating the protective role of bile 
pigments. One of these was published by Dennery and co-workers (1995). In 
this study hyperbilirubinemic Gunn rats were exposed to a hyperoxia 
(>95 % O2) atmosphere for 3 days. Oxidative markers were inversely correlated 
to serum bilirubin concentrations [DENNERY et al., 1995].  
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Another important work demonstrating the antioxidative role of bilirubin in vivo 
was published by Noriega et al [2003]. They examined the effects of bilirubin 
(5 mmol/kg body weight) in aminolevulinic acid (ALA) induced liver damage in 
Wistar rats by intraperitoneal injection. This study showed that bilirubin can act 
as an efficient antioxidant against oxidative cell damage induced by ALA 
[NORIEGA et al., 2003]. 
 
2.5.3. Bilirubin as protector against cardiovascular diseases 
Bulmer et al. (2007) investigated bilirubin as protector against cardiovascular 
diseases in patients with GS. The study demonstrated that people with GS 
shown an improved resistance to serum oxidation and thus show a reduced 
prevalence of cardiovascular disease compared to a control group. In 
conclusion, it was suggested that higher levels of bilirubin can increase the 
status of circulating antioxidants and improve resistance to serum oxidation and 
may protect from prevalence of developing cardio vascular diseases (CVD) 
[BULMER et al., 2008a]. 
Some other studies showed that there is a low prevalence of coronary artery 
disease or ischemic heart disease in people with GS or generally in people with 
higher bilirubin levels. There is probably an increasing serum antioxidant 
capacity in people with higher serum bilirubin levels that prevent the occurrence 
of ischemic heart diseases [VITEK et al., 2002; SCHWERTNER et al., 1994]. A 
negative correlation between serum bilirubin levels and atherosclerosis was 
shown and these results might indicate the importance of bilirubin in the 
prevention of cardiovascular diseases or in general oxidative-stress mediated 
diseases [NOVOTNY and VITEK, 2003]. 
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2.5.4. Bilirubin and DNA damage and cancer 
Overwhelming amounts of reactive oxygen species of endogenous or 
exogenous origin can cause damage to DNA. DNA lesion that remains 
unrepaired, increase the prevalence of mutations which play a key role during 
carcinogenesis.  
Bilirubin was shown to be a strong antioxidant that can prevent the oxidation of 
several biomolecules. There are only few studies that show the protective effect 
of bilirubin towards DNA oxidation and its role in the possible prevention in the 
etiology of cancer. The few numbers of studies, which investigate the effect of 
bilirubin levels, deliver conflicting results [ZUCKER et al., 2004]. 
In the study of Asad et al. (2000) it was shown, that 50 µM of bilirubin were able 
to reduce the amount of oxidative DNA single strand breaks in calf thymus DNA 
induced by L-Dopa-Cu(II) by 50 %. A concentration of 20 µM bilirubin reduced 
the generation of hydroxyl radicals by 30 %. The results of this study suggest 
that any increase from normal bilirubin levels under conditions of oxidative 
stress would be able to afford protection of cellular DNA from L-Dopa-Cu-(II)-
mediated damage [ASAD et al., 2000]. 
Two years later (2002) the same research group of Asad and co-workers 
showed, that bilirubin has pro-oxidant effects upon DNA due to its ability to bind 
with  the transition metal ions Cu(II) and in the following form a bilirubin CU(II)-
DNA complex which causes oxidative DNA cleavage [ASAD et al., 2002]. 
Throughout a study by Rao et al. additionally the effect of bilirubin on DNA 
damage was investigated using the comet assay. Cells treated with bilirubin 
showed a typical comet tail indicating that bilirubin causes DNA damage. This 
study showed that bilirubin has anti-cancer activity as a prooxidant [RAO et al., 
2006]. 
In a Belgian prospective study the correlation of serum bilirubin and 10-year 
mortality risk including all cause, cardiovascular and cancer mortality was 
assessed in a Belgian population. The results showed that men with higher 
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serum bilirubin levels had a significant reduced risk of non-lung cancer 
mortality. In women the same trend was observed but lacking statistical 
significance. There was no significant association detectable between serum 
bilirubin and cardiovascular mortality in neither men nor women [TEMME et al., 
2001]. 
In the USA, a prospective study on the potential chemopreventive function of 
bilirubin was investigated by Zucker et al. (2004). Data of the study showed that 
bilirubin levels vary significantly with gender, race and smoking status. Men 
have higher bilirubin levels compared to women. Serum bilirubin levels were 
lower in active smokers compared to non-smokers. Total serum bilirubin levels 
were also lower in subjects which reported prior nondermatological cancer in 
comparison to subjects who did not have a history of nondermatological 
malignancy. The results of the study showed that an increase in serum bilirubin 
by 1.0 mg/dl leads to a decreased prevalence of colorectal cancer (odds 
ratio: 0.257). The inverse relationship between serum bilirubin and colorectal 
cancer was more robust for women. There was also an inverse relationship 
between serum bilirubin and non-gastrointestinal cancers but at a lower level 
(odds ratio: 0.809) [ZUCKER et al., 2004]. 
Very recently a cohort study examined the relationship between serum bilirubin 
levels and respiratory diseases and lung cancer among adults in UK. Incidence 
of lung cancer was assessed and the results showed that an increase in 
bilirubin level of 0.1 mg/dl was accompanied by an 8 % decreased lung cancer 
incidence in men and 11 % decreased lung cancer incidence in women 
[HORSFALL et al., 2011]. 
Bilirubin is considered as a strong endogenous antioxidant and it is discussed 
that slightly elevated bilirubin levels have beneficial functions for health. With 
the present study we aimed at investigating the protective effect of bilirubin at 
DNA level and to measure its protective effect using the comet assay. By doing 
so, the DNA damage of individuals with GS (and hence elevated levels of 
bilirubin) and a control group (with normal levels of bilirubin) was compared.
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3. Material and Methods 
3.1. Study design and in- and exclusion criteria 
In the present case-control-study 45 subjects with Gilbert’s syndrome (GS) and 
39 healthy persons as control group (C) were included. Due to their UCB level 
very close to 1 mg/dl 16 persons could clearly not be allocated to one of the 
groups. There was a difference between first and second blood sampling in 
reaching threshold values. For a clear allocation an additional blood sampling or 
determination of genotype would be needed. The aim of the study was to 
observe whether people with GS have a lower DNA damage than controls. 
Cases and controls were matched for age and sex. The experimental design is 
summarised in Figure 10. 
 
 
Figure 10: Illustration of the experimental design 
Participants were recruited by information-sheets in different buildings and 
places (hospitals, universities, pharmacies ...). In order to assess relevant 
parameters, blood was withdrawn from all participants at the beginning of the 
study at the General hospital (AKH). Inclusion and exclusion criteria were 
checked in combination with questionnaires. 
Total Participants
(n=100)
Case                                       
Participants with  
Gilbert's Sydrome
(n=45)
Elevated blood 
level of UCB
Control 
(n=39)
Normal blood level of 
UCB
Not definable*
(n=16)
level around splitting 
value of UCB
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A second blood sampling was performed at the AKH for the main parameter 
and besides urine collection, buccals cells were obtained. 
In order to carry out the Comet assay, one of the main methods for measuring 
DNA damage in peripheral blood mononucleated cells (PBMCs), the blood 
samples were immediately trasported to the Department of Nutritional Sciences 
at the “University of Vienna”. By applying the Comet assay it was observed 
whether people with GS are better protected against oxidative DNA damage 
than controls with lower bilirubin levels.  
Inclusion criteria: 
 Age: 20-80 years 
 total bilirubin level > 1.2 mg/dl [20.52 µmol/l] (GS) 
 unconjugated bilirubin level  > 1.0 mg/dl [17.1 µmol/l] (GS) 
 total bilirubin level <1.2 mg/dl [20.52 µmol/l] (Control) 
 unconjugated bilirubin level <1.0 mg/dl [17.1 µmol/l] (Control) 
 Gamma-Glutamytransferase (GGT) <39 U/l (women) <66 U/l (men) 
 Alanin Aminotransferase (ALT) <35 U/l (women) <50 (men) 
 Aspartat Aminotransferase (AST) <35 U/l (women) <50 U/l (men) 
 Moderate fitness 
Exclusion criteria: 
 < 20 years or > 80 years 
 Cardiovascular diseases 
 Hepatitis B/C 
 Liver diseases 
 Cholelithiasis 
 Haemolysis 
 Heart diseases 
 Chronical kidney disease 
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 Acute tumor 
 Diabetes Mellitus 
 Supplementation of antioxidant within the last 4 weeks before the first 
blood sampling 
 No intake of drugs which affect liver parameters (eg. Probenecid, 
Rifampicin) within the last 5 weeks before the first blood withdrawal 
 Smokers >5 cigarettes a day 
 People with organ transplantation 
 Competitive athletes (>10 hours training per week) 
3.1.1. Isolation of peripheral blood mononucleated cells 
 Whole blood was sampled by venipuncture in heparinized tubes. 
 7 ml of anticoagulant whole blood was filled in 12 ml Leucosep tubes. 
 Tubes were centrifuged at 1000 rcf for 15 Min. at 16 °C (without brake). 
 The enriched fraction of lymphocytes, in particular peripheral blood 
mononucleated cells (PBMCs) were gently pipetted into a 15 ml 
centrifuge tube and filled up with 4 °C cold PBS-Buffer to a total volume 
of 15 ml. From here all steps were executed on ice. 
 Tubes were centrifuged at 304 rcf for 15 Min. at 22 °C (with brake). 
 Supernatant was discarded and PBMC pellet was washed in 10 ml of 
PBS-buffer. 
 Tubes were centrifuged at 304 rcf for 10 Min. at 22 °C (with brake). 
 Supernatant was gently discarded and PBMC pellet was suspended in 
1 ml of PBS for cell counting.  
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3.1.2. Cell counting determination 
To ensure a sufficient cell number per slide and to prevent overlapping of cells 
(if cell concentration is too high), a defined cell concentration of 1x 106 cells/ml 
is necessary for the comet assay procedure. Furthermore a total suspension 
volume of 250 µl is needed. For cell count determination the automated cell 
counter “Countess” from Invitrogen was used. 
A cell suspension of appropriate concentration (approximately 106  cells/ml) was 
prepared; therefore 20 µl of cell suspension was diluted in 60 µl PBS-buffer in a 
cup. 10 µl cell suspension was mixed with 10 µl 0.4 %Trypan blue (1:1). Finally, 
10 µl were transferred in a chamber on a slide and inserted into the “Countess 
Invitrogen”. 
 
3.2. General principles of the Comet assay 
Comet assay is a widely used method for measuring DNA damage. The cells 
are embedded in agarose on a microscope slide. Lysis is used for removing 
membranes, cytoplasm and nucleoplasm. After treatment with H2O2 DNA strand 
breaks are occurring and different enzymes are used to detect oxidised 
pyrimidenes (ENDOIII) and oxidised purines (FPG).  
In an electric field at an alkalised level (electrophoresis), damaged DNA 
migrates faster than the compact and undamaged DNA. After staining, the 
different intensities of the formed “comets” can be evaluated with a fluorescence 
microscope [COLLINS, 2004]. 
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3.3. Comet Assay 
3.3.1. Equipment for Comet Assay 
 
Table 1: Equipment for Comet Assay 
Material Company Product number 
 
Analytical balance 
 
 Mettler 
 
AT201 
Balance  Mechatronics   
Austria 
41107690 
Calibration solution   HANNA instruments  
Centrifuge  Eppendorf 5417R 
Computer   
Countess-automated cell counter  Invitrogen  
Countess-cell counting chamber 
slides 
  Invitrogen  
Drying chamber   Memmert GmbH Modell 500; 
D06061 
Electrophoresis   Biozym Serial no: C5 
08091040; Stock 
Code: CSL-10M40 
Examination gloves   Microflex  
Heating Plate/Magnetic stirrer   Heidolph MR 3001K 
Microscope   Zeiss, Hitachi  
Microscope slides   VWR ECN 631-1551 
Microscope Cover glasses 
(22x22 mm, 20x20 mm) 
  VWR ECN 631-1570 
Microwave   Elta  MW 170 (17MXS1); 
320V 50Hz 700W 
Moist box   
Nitrile Examination gloves   Mikroflex 9953.01 
pH-meter   Metrohm 691 pH-meter 
Staining dishes   Hellendahl 2460 
Silver tray   
Water bath (37 °C, 55 °C)   
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3.3.2. Reagents for Comet Assay 
Table 2: Chemicals and Reagents for Comet Assay 
Reagents   Company   Product  number 
 
 
Albumin from bovine serum (BSA) 
 
Sigma Life science 
 
  A2153-50G 
Dulbecco´s Phosphate Buffered 
Saline (PBS) 
Sigma Life science   D5837 
Ethylenediamine tetraacetic acid 
(EDTA) 
Sigma Life science   E6758 
Ethidium bromide aqueous solution Sigma Life science   E1510 
Hydrochloric Acid (HCL) Riedel-de Haen  
4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES) 
Sigma Life science   H3375 
Hydrogen peroxide solution 
30 wt % solution in water (H2O2) 
Sigma Life science  
Potassium chloride (KCl)   Riedel-de Haen  31248 
Potassium hydroxide (KOH)   Sigma–Aldrich  60370 
Sodium Chloride (NaCl)   Sigma-Aldrich   71380 
Sodium Hydroxide (Pellets) 
(NaOH) 
  Riedel-de Haen   06203 
Trizma base (Tris)   Fluka Analytical   93350 
Triton X-100   Sigma-Aldrich  
Trypan blue stain 0.4%   Invitrogen   T10282 
Ultra Pure Agarose (NMA)   Invitrogen   153001 
Ultra Pure LMP Agarose (LMA)   Invitrogen   144556 
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3.3.3. Manufacturing process and storage of solutions for 
Comet Assay 
The reagents, used for the comet assay process, were manufactured according 
to the protocol “Protocol for the single cell gel electrophoresis/Comet Assay for 
rapid genotoxicity assessment” published by Dhawan et al (w.y.). 
Alkaline electrophoresis buffer (pH > 13) 
24 g NaOH (0.3M) 
580 mg EDTA (0.001M) 
NaOH and EDTA were dissolved in 2 l double distilled H2O. PH should be 
higher than 13 and can be adjusted with NaOH. Stored at 4 °C in the cooling 
chamber. 
Enzyme reaction buffer for FPG and ENDOIII 
9.53 g HEPES (40 mM) 
7.46 g KCl (0.1 M) 
0.15 g EDTA (0.5 mM) 
0.2 g BSA (0.2 mg/ml) 
HEPES, KCL, EDTA and BSA were dissolved in 1 l double distilled H2O and 
adjusted to pH 8.0 with KOH (1M). This buffer could also be made as 10x stock 
(adjusted with KOH (5M), be filled in aliquots and stored at -20 °C. Before 
usage the pH has to be controlled and adjust to 8 with KOH (5M). 
H2O2 Stock solution 
103 µl Hydrogen peroxide solution (30%) 
Double distilled H2O 
103 µl of the hydrogen peroxide solution was mixed with 10 ml double distilled 
H2O to receive a 0.1M stock. Before usage 80 µl of this 0.1M stock were mixed 
with 79.92 ml double distilled water and stored at 4 °C in the cooling chamber. 
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Lysis Solution (pH = 10) 
146.1 g NaCl (2.5M) 
29.2 g EDTA (0.1M) 
1.211 g Tris (10mM) 
Double distilled H2O 
Triton X-100 
NaCl, EDTA and Tris were dissolved in 1 l double distilled H2O and the pH was 
adjusted to 10 with NaOH (10M). Solution was stored at room temperature. 
Triton X-100 (1 ml per 100 ml) was added immediately before use and then the 
solution was stored at 4 °C in the cooling chamber. 
NaOH (10N) 
400 g NaOH 
Double distilled H2O 
400 g NaOH were dissolved in 1 l double distilled H2O to receive a 10N NaOH 
solution. Stored at room temperature. 
Neutralization buffer (pH = 7.5) 
48.44 g Tris base (0.4M) 
Double distilled H2O 
48.44 g Tris base (0.4M) were dissolved in 1 l double distilled H2O and the pH 
was adjusted to 7.5 with 37 % HCl. Buffer was stored at 4 °C in the cooling 
chamber. 
Normal Melting Agarose (NMA) 
1000 mg NMA 
Double distilled H2O 
1000 mg NMA were dissolved in 100 ml double distilled H2O, heated in 
microwave and stored at 4 °C in the cooling chamber. Before usage the 
agarose was heated up again in the microwave until it was liquefied. 
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Low Melting Agarose (LMA) 
800 mg LMA 
80 ml PBS 
800 mg LMA were dissolved in 80 ml PBS, heated in microwave and stored at 
4 °C in the cooling chamber. Before usage the agarose was heated up again in 
the microwave until it was liquefied. 
Ethidium bromide solution 
20 µl ethidium bromide solution 
Double distilled H2O 
20 µl of ethidium bromide solution was mixed with 10 ml double distilled H2O to 
receive a concentration of 20 µg/ml. Stored at 4 °C in the fridge. 
3.3.4. Protocol for Comet Assay 
The Comet Assay was carried out according to the advices of “Protocol for the 
single cell gel electrophoresis/Comet Assay for rapid genotoxicity assessment” 
published by Dhawan et al. (w.y.). 
The general activity during the comet assay is illustrated in Figure 11. 
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Figure 11: General activity of comet assay (left) and specific gels treatment (right) 
For lysis ‘no treatment’, FPG, ENDOIII and buffer 3 slides were prepared and 2 
slides for H2O2. Each slide contained two gels and 2 subjects (S1, S2) all 
together 14 slides were prepared for 2 participants.  
Slides treated with lysis stayed in lysis solution during the entire time, whereas 
H2O2 slides were first treated with hydroperoxide and subsequently kept in lysis 
solution until electrophoresis. Slides treated with buffer, FPG or ENDOIII stayed 
in lysis solution (at least 75 minutes) until incubation with enzymes started. See 
also Figure 11. 
Slide preparation: 
 Prepared NMA was heated 3 times in the microwave until it was completely 
liquefied and dissolved. Jar with dissolved NMA was transferred into a water 
bath and kept at 55 °C. 
 Slides were then dipped in the NMA-agarose and excess agarose was 
drained off. The backs of the slides were then wiped with a paper towel. 
Slides were air dried overnight, before they were stored at room 
temperature.  
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Embedding cells in agarose: (see Figure 12) 
 Prepared LMA was heated 3 times in the microwave until it was completely 
liquefied and everything was properly dissolved. Subsequently LMA was put 
into a warm water bath and kept at 37 °C. 
 Slides precoated with NMA were labelled with subject number and the kind 
of treatment: “lysis”,”H2O2”, “buffer”,” FPG” and “ENDOIII”. 
 30 µl of cell suspension (with a concentration of c= 1x106 cells per ml) was 
resuspended in an extra cup with 140 µl LMA.  
 70 µl of this mixture were quickly pipetted on a precoated slide, which was 
placed on cooled trays. Trays were kept in the cooling chamber before 
usage. Each slide had space for two spots with a volume of 70 µl.  
 Each slide was immediately covered with one cover slip (20x20 mm) and 
stayed in the cooling chamber for a minimum of 5 minutes before the cover 
slips got removed. During this time the agarose set. 
Treatment with H2O2: 
 After the cover slips have been removed from the slides, they were placed in 
a staining jar containing a cooled H2O2-solution (100 µM) and incubated for 
5 minutes in a cooling chamber (4 °C). 
 Then the slides were washed 3 times in PBS to remove H2O2. 
Lysis: 
 The lysis solution (lysis solution with 1 % triton X) was filled into jars. 
  After H2O2 incubation and removing the cover slips from all other slides, 
they were placed in the prepared lysis solution for 75 minutes in the cooling 
chamber. 
 Slides without H2O2 incubation were incubated separately from slides with 
H2O2 incubation. 
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Enzyme treatment: 
 Enzyme reaction buffer was prepared. 
 Slides for enzyme incubation (“buffer”, “FPG” and “ENDO III”) were washed 
in staining jars with enzyme reaction buffer (4 °C) 3 times for 5 minutes 
respectively. 
 Enzyme dilutions (1:3000) were prepared.   
 Buffer was drained off the slides.  
 The agarose embedded cells (note: 2 gels/slide) were covered with 50 µl of 
either enzyme solution (FPG or ENDOIII) or enzyme reaction buffer (as 
negative control) and cover slips (22x22 mm). Slides were placed in a moist 
box and incubated in a drying chamber at 37 °C for 30 minutes.  
 Meanwhile all other slides (H2O2 and “lysis”) stayed in the lysis solution.  
Alkaline treatment and electrophoresis: (see Figure 13) 
 All cover slips were removed before they were placed in the electrophoresis. 
 The electrophoresis tank was placed in the cooling chamber at 4 °C. 
 Slides were placed on the platform in the electrophoresis tank with the gel 
upwards and the labelling areas towards the same direction. Incomplete 
rows were filled up with precoated but blank slides. (In every electrophoresis 
42 microscope slides had place that means 5 samples and one control 
sample.) 
 Slides were incubated in alkaline electrophoresis buffer for 20 minutes. 
(unwinding phase) 
 After the alkaline treatment, the electrophoresis was performed for 
30 minutes at around 300 mA, 25 V and 8 W. The current was adjusted by 
adding (if too low) or removing (if too high) alkaline electrophoresis buffer at 
a switched off power supply.  
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Neutralisation: 
 Slides were taken out from the electrophoresis and neutralized by rinsing 
5 minutes in cold neutralization buffer and another 5 minutes in double 
distilled water at 4 °C.  
 Finally the slides were dried at room temperature overnight in darkness and 
stored until staining.  
Staining: 
 30 µl of the ethidium bromide solution (20 µg/ml) was placed on the slide 
and covered with a coverslip (22x22 mm). 
 For examination two out of three slides were selected and at any time 50 
cells per gel were counted. In case values of the two slides differed too 
much the third one was additionally determined.  
     
Figure 12: Slides on the tray before start of embedding cells in agarose. 
       
Figure 13: Electrophoresis (left) and lab work (right) 
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3.4. Statistical Analysis 
Statistical analysis of all the data was performed with the program ”Statistical 
Program for Social Sciences (SPSS) version 17.0 for Windows,”. At first, the 
boxplot was used in order to identify extreme values. All the data were proved 
for normal distribution using the 1-sample Kolmogorow-Smirnow-Test (KS-
Test). For two- group Comparison of genomic damage (e.g. Gilbert and Control) 
the “Independent sample t-Test” was used as all data were normally distributed. 
The ANOVA-test (Tukey- HSD) was used for three- or more-group Comparison 
(e.g. Bilirubin tertiles). Correlations between variables were tested using the 
bivariate “Pearson Correlation”. Finally a stepwise linear regression analysis 
was performed.  
All results are expressed as mean values ± standard deviation (SD). 
Differences with p value < 0.05 were considered as statistically significant. 
The subjects were divided in 2 groups according to the level of unconjugated 
bilirubin. The groups were respectively “Gilbert’s Syndrome” (UCB levels 
>1 mg/dl; [17, 1 µmol/l]), “Control” (UCB levels <1 mg/dl; [17, 1 µmol/l]). 
Additionally a third group ‘not defineable’ was formed, which included subjects 
that could not be allocated to either one of the groups because bilirubin levels 
were close to 1 mg/dl. When DNA damage in Gilbert’s syndrome and control 
group was compared, data of the ‘not defineable group’ were excluded from 
statistical analysis. Furthermore DNA damage was compared after dividing the 
study population into three similar groups of bilirubin levels; group 1 (low 
bilirubin levels (0.24- 0.65 mg/dl)[ 4.1-11.1 µmol/l], group 2 (moderate bilirubin: 
0.66 -1.21 mg/dl [ 11.3-20.7 µmol/l] and group 3 (high bilirubin: 1.22 -4.3 mg/dl 
[20.9-73.5 µmol/l ] (with ‘not defineable’ included n = 16). 
Moreover, the data was stratified for age and gender. The two age groups were 
respectively ‘young’ (test persons < 30 years) and ‘older’ (test persons ≥ 30 
years). 
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In this work obtained results for DNA single- and double-strand breaks detected 
by lysis in Gilbert’s syndrome and control are discussed. Moreover oxidative 
DNA damage in terms of FPG- sensitive sites and ENDO III- sensitive sites are 
demonstrated and discussed in detail. Results for lysis and resistance towards 
oxidative damage by oxidative challenge with H2O2 are demonstrated and 
discussed in the work of Barbara Rittmannsberger “Evaluation of DNA Damage 
in Gilbert’s Syndrome Subjects in H2O2-treated and untreated PBMCs”.   
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4. Results and discussion 
The framework of this work aimed at investigating the relationship between 
bilirubin level and DNA damage. Moreover, it should be explored whether 
individuals with Gilbert’s syndrome and characteristically increased bilirubin 
concentrations show improved resistance towards DNA damage in comparison 
to controls.  
The study population consisted of 103 subjects. Later on 3 subjects were 
excluded from the study, because one subject turned out to be a smoker, one 
showed abnormal blood glucose levels and one had a BMI > 35. The 
descriptive statistic of the study population can be found in Table 3. 
Table 3:  Description of the study population 
 Gilbert Control Not defineable 
Number 45 39 16 
Men 35 23 12 
Women 10 16 4 
Age (years) 33 ± 13 32 ± 12 26 ± 6 
UCB  (mg/dl) 1.9 ± 0.83 0.5 ± 0.19 0.7 ± 0.21 
Data are means ± SD. UCB: Serum concentration of unconjugated bilirubin. 
4.1. DNA damage 
Data of the comet assay were statistically analysed for 98 subjects from a total 
of 100; 2 values were excluded from further analysis because they showed 
extremely high values for DNA damage and hardly any cells were on the 
microscopic slide.  
Mean DNA damage expressed as % DNA in tail in the whole study population 
for lysis was 5.1 ± 1.23; for FPG– sensitive sites (oxidised purines) 4.9 ± 2.77 
and for ENDO III– sensitive sites (oxidised pyrimidines) 2.2 ± 1.25. 
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4.1.1. DNA damage in Gilbert’s Syndrome and Control 
Subjects were divided in 2 groups according to the level of unconjugated 
bilirubin which was detected by HPLC (further details can be obtained from the 
diploma thesis of Katharina Marisch “The DNA protecting effect of unconjugated 
bilirubin”). The groups were respectively “Gilbert’s Syndrome” (UCB levels 
>1 mg/dl; [17, 1 µmol/l]), “Control” (UCB levels <1 mg/dl; [17, 1 µmol/l]). Table 4 
summarises the results of DNA damage in Gilbert and control. 
Table 4: DNA damage in Gilbert's syndrome and Control 
 Gilbert’s Syndrome Control pValue 
Number 45 37  
% DNA in tail Lysis 5.3 ± 1.35 5.0 ± 1.18 0.252 
% DNA in tail FPG 5.3 ± 3.13 4.6 ± 2.32 0.231 
% DNA in tail ENDO III 2.1 ± 1.17 2.5 ±1.38 0.245 
 
There were no significant differences in mean DNA damage in Gilbert and 
control group in strand breaks and FPG- or ENDO III- sensitive sites. The mean 
values for single- and double-strand breaks (lysis) in Gilbert were slightly higher 
(6 %) compared to the control group. FPG- sensitive sites were 15.2 % higher in 
the Gilbert group. Values of ENDO III- sensitive sites were 16 % lower in the 
Gilbert group in comparison to the control group but not significantly.  
    
Figure 14: DNA damage in Gilbert's syndrome and Control 
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We expected lower DNA damage in the Gilbert group due to elevated bilirubin 
levels and its strong proposed antioxidative potential. This is the first study 
which investigated the effect of elevated bilirubin towards genotoxicity using the 
comet assay. Thus, the results cannot be compared with existing literature. In 
order to detect the protective effect of bilirubin at DNA level further research is 
needed.  
Throughout the whole study population, higher mean values of % DNA in tail for 
FPG- sensitive (4.9 ± 1.23) sites compared to Endo III- sensitive sites (2.2 ± 
1.25) were found. This is comparable to other study results [BOTTO et al., 
2002; MOSER et al., 2011].  
An explanation for higher FPG values is that, in the comet assay, the FPG 
protein detects 8-oxo-dG (8-Oxo-7, 8-dihydro-2’-deoxyguanosine) which is 
easily formed and the most frequent DNA lesion [MOLLER and LOFT, 2006]. 
Besides oxidative damaged purines, FPG also detects alkylation damage 
especially N-7 alkylation of guanine with high sensitivity. There are low 
background levels of alkylated bases in normal human lymphocytes caused by 
various endogenous mechanisms or by exogenous alkylating substances. Thus, 
increased values of FPG cannot be directly linked to increased presence of 
oxidative damage. ENDO III on the contrary detects solely oxidised pyrimidines 
and is more specific for oxidative DNA damage [SPEIT 2004; COLLINS et al., 
2001; DUSINSKA and COLLINS 2008].  
There is a relatively high intra- and interindividual variation in the basic level of 
DNA damage among healthy individuals which can be explained by the 
individual and interlaboratory factors [DUSINSKA and COLLINS 2008].  
Some authors also indicate that a state of oxidative stress is required to 
observe the antioxidant properties of compounds more effectively. As most 
subjects were relatively young and all non-smokers (up to 5 cigarettes) it can be 
assumed, that level of oxidative stress in the subjects was low.  
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4.1.2. DNA damage in bilirubin tertiles 
Furthermore the total study population was divided into three similar groups 
according to their serum concentration of unconjugated bilirubin (bilirubin 
tertiles). This was done to detect the impact of differing bilirubin levels on DNA 
damage more precisely. The mean values for DNA damage in the three groups 
of bilirubin are demonstrated in Table 5. 
Table 5: DNA damage and bilirubin tertiles 
 Tertile 1: 
0.24-0.65 
mg/dl 
Tertile 2: 
0.66 -1.21 
mg/dl 
Tertile 3: 
1.22 -4.3  
mg/dl 
pValue 
Number 31 34 33  
% DNA in tail Lysis 4.9 ± 1.21 5.3 ± 1.14 5.1 ± 1.33 0.328 
% DNA in tail FPG 4.7 ± 2.43 5.1 ± 3.08 4.8 ± 2.81 0.833 
% DNA in tail ENDO III 2.3 ± 1.29 1.9 ± 1.32 2.2 ± 1.12 0.410 
 
There were no significant differences between the 3 different bilirubin levels and 
DNA damage (see Figure 15). 
 
Figure 15: DNA damage in bilirubin tertiles (lysis) 
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4.1.3. Influencing factors on oxidative DNA damage 
4.1.3.1. Age  
In order to evaluate the impact of age on the level of oxidative DNA damage the 
subjects were allocated to two different age groups; young subjects < 30 years 
and old subjects ≥ 30 years. Results for mean DNA damage in Gilbert and 
control after stratification for age are summarised in Table 6. 
Table 6: DNA damage in Gilbert and Control in two age groups (< 30 years; ≥30years) 
  Gilbert’s 
Syndrome 
Control pValue 
< 30 years Number 26 23  
 % DNA in tail Lysis 5.2 ± 1.35 4.8 ± 1.14 0.217 
 % DNA in tail FPG 5.9 ± 3.74 5.1 ± 2.33 0.353 
 % DNA in tail ENDO III 2.2 ± 1.07 2.5 ± 1.35 0.360 
≥ 30 years Number 19 13  
 % DNA in tail Lysis 5.4 ± 1.37 5.3 ± 1.21 0.831 
 % DNA in tail FPG 4.5 ± 1.84 3.7 ± 2.14 0.267 
 % DNA in tail ENDO III 2.1 ± 1.31 2.4 ± 1.49 0.540 
 
There were no significant differences in mean DNA damage in Gilbert’s 
syndrome and control after the stratification for age. 
Mean values of strand breaks and FPG- sensitive sites were slightly but 
insignificantly elevated in the Gilbert group in comparison to the control group. 
In younger subjects < 30 years, subjects with Gilbert’s syndrome showed higher 
DNA damage for lysis (8.3 %) and for FPG- sensitive sites (15.7 %). In old 
subjects > 30 years, Gilbert subjects showed higher mean values for lysis 
(1.9 %) and values of FPG sensitive sites (21.6 %). On the contrary mean 
ENDO III- sensitive sites were lower in Gilbert’s syndrome in both age groups < 
30 years (12 %) and in subjects’ ≥ 30 years (12.5 %) See Figure 16.  
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Figure 16: DNA damage in Gilbert's syndrome and Control and age 
 
In Table 7 results for the impact of age on DNA damage in the whole study 
population are summarised.  
 
Table 7: Impact of age on DNA damage in the whole study population 
 < 30 years ≥ 30 years pValue 
Number 61 37  
% DNA in tail Lysis 5.0 ± 1.20 5.3 ± 1.28 0.233 
% DNA in tail FPG 5.2 ± 3.10 4.3 ± 2.16 0.076 
% DNA in tail ENDO III 2.2 ± 1.23 2.1 ± 1.29 0.906 
                
   
Figure 17:  Impact of age on DNA damage in the whole study population 
For all test persons splitted in two age groups, the results show that older 
subjects had slightly higher mean DNA damage (lysis) compared to younger 
people. However, the statistical significance was lacking. In the whole study 
population mean in strand breaks was 5.7 % lower in subjects < 30 years in 
comparison with people ≥ 30 years.  
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Concerning FPG- and ENDO III- sensitive sites, the opposite was observed. 
Values for FPG- sensitive were 20.9 % higher in subjects < 30 years and ENDO 
III was 4.7 % higher in subjects < 30 years. 
 
Figure 18: DNA damage and bilirubin tertiles in subjects < 30 years (lysis), * p<0.05 
After dividing the study population into 3 groups of bilirubin levels, a significant 
difference in the mean values of strand breaks (p= 0.016) was observed in 
subjects < 30 years (see Figure 18). Thus subjects with moderate levels of 
bilirubin 0.66- 1.21 mg/dl had significantly higher mean values of DNA damage 
in comparison with subjects with low bilirubin levels 0.24- 0.65 mg/dl.  
There are only few studies which explored the effect of age on DNA damage 
measured by the comet assay. The studies concerning age and basal DNA 
damage, failed to show a clear effect of age and the results are still inconsistent 
[MOLLER et al., 2000].  
Humphreys et al. aimed to investigate the effect of age on oxidative DNA 
damage using the alkaline comet assay and included FPG enzymes. The 
subjects were divided into three age groups (group 1: 20-35 years, group 2: 63-
70 years and group 3: 75-82 years). The two older groups showed significantly 
decreased DNA damage in terms of H2O2- induced strand breaks compared to 
the younger group. The rate of oxidised purines was significantly higher in the 
* 
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oldest group in comparison with the two younger groups [HUMPHREYS et al., 
2007].  
In 2006 Dusinska et al., used the comet assay with FPG and detected a highly 
significant positive correlation between FPG- sensitive sites as well as between 
ENDO III- sensitive sites and age. The study included 239 Slovakian workers 
exposed to asbestos and 139 unexposed control subjects. In males single 
strand breaks increased with age but not in females. The subjects were 
between 21 and 88 years old, majority of the subjects were in the middle of the 
range [DUSINSKA et al., 2006]. 
In the study of King and co-workers DNA damage in four different age groups 
(Group 1: 35-39 years, Group 2: 50-54 years, Group 3: 65-69 years and 
Group4: 75-80 years) was measured. Results showed that there was no 
increase in mean DNA damage between groups 1, 2 and 4. Interestingly study 
subjects of group 3 showed highest level of DNA damage [KING et al., 1997].  
Krajcovicová-Kudlácková and co-workers investigated DNA damage in relation 
to diet and age in 161 non- smoking women. DNA damage (DNA strand breaks, 
oxidised purines or oxidised pyrimidines) was measured in young women 20-30 
years (46 vegetarians, 48 non-vegetarians) and older women 60-70 years (33 
vegetarians, 34 non-vegetarians). In non-vegetarian women older subjects had 
significantly higher values of oxidised bases compared to younger subjects. In 
vegetarians, values were age-independent [KRAJCOVICOVÁ-KUDLÁCKOVÁ 
et al., 2008]. 
 Further, the study of Kazimírová and co-workers showed significant positive 
correlation between age and oxidative DNA damage (net FPG- sensitive sites) 
in healthy non-vegetarian (average age 40 ± 1.7 years, ranging from 20 to 62). 
In vegetarians (average age 41 ± 2.0 years ranging from 20 to 69), there was a 
trend towards a negative association between age and FPG- sensitive sites 
[KAZIMÍROVÁ et al., 2006]. 
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Nevertheless there are numerous studies which failed to show a correlation 
between DNA damage and age. For example in the study of Betti et al., no 
relation between age and DNA damage was found. The amount of strand 
breaks in DNA was measured in human lymphocytes from 200 healthy subjects 
using the comet assay [BETTI et al., 1995]. Another study also failed to show a 
significance impact of age on DNA damage in 160 elderly subjects (group 1: 60 
-69 years and group 2: > 70 years). Younger subjects tended to show lower 
values of strand breaks in comparison to older subjects although lacking 
statistical significance [Mendoza-Núñez et al., 2001]. Furthermore in a very 
recent study including 60 healthy male and 30 healthy females (25-35 years), 
there was no significant difference concerning age and basal DNA damage 
measured with the comet assay [DIXIT, 2011]. 
Aging is often accompanied by increased oxidative stress, due to higher rates of 
free radicals (ROS), a declined antioxidative system, reduced DNA repair and 
consequently increased rates of damage of important biomolecules. Throughout 
aging, increased rates of ROS are produced in the body resulting mainly from 
leakage of ROS of aged mitochondria [HUMPHREY et al., 2007]. 
In the current study FPG- sensitive sites were decreased in subjects ≥ 30 years 
without any statistical significance. It is possible that increased release of ROS 
during aging simultaneously stimulates DNA repair and also antioxidative 
defence in the body in order to protect the body against genomic damage 
accompanied by ageing [HUMPHREY et al., 2007].  
In the study of Humphrey it was shown that the rate of DNA repair of 8-oxo 
guanine increases with age [HUMPHREY et al., 2007].  
An important note has to be made on the study population. Subjects were 
divided into two age groups and all the subjects over the age of 30 were 
allocated to the older group. Most of the people in the study were around the 
age of 30 and only very few subjects were over 60 years (see Figure 19). The 
group of old subjects would have become too small to reach any statistical 
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power. 30 years cannot be considered as old and it can be assumed that a 
person aged 30 has a proper antioxidative defence system which copes 
effectively with the attack of free radicals. The small number of older subjects 
may be the reason why there were no significant differences in mean DNA 
damage in age. Further investigations in older people are necessary to 
investigate the impact of age on DNA damage. For getting more statistical 
power, it would be important to extend the number of subjects. 
 
Figure 19: Distribution of age in the study population 
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4.1.3.2. Gender 
The level of DNA damage in Gilbert and control were also compared after 
stratification of data in men and women. The results for the impact of gender on 
DNA damage in Gilbert’s syndrome and control are summarised in Table 8. 
Table 8: DNA damage in Gilbert and control and gender 
  Gilbert’s 
Syndrome 
Control pValue 
Men Number 35 22  
 % DNA in tail Lysis 5.5 ± 1.27 5.1 ± 1.23 0.245 
 % DNA in tail FPG 5.4 ± 3.28 5.0 ± 2.46 0.588 
 % DNA in tail ENDO III 2.2 ±1.05 2.7 ± 1.38 0.157 
Women Number 10 15  
 % DNA in tail Lysis 4.5 ± 1.35 4.7 ± 1.12 0.626 
 % DNA in tail FPG 4.9 ± 2.65 3.9 ± 2.03 0.326 
 % DNA in tail ENDO III 2.0 ± 1.54 2.2 ±1.38 0.749 
  
 
No significant differences were observed in mean DNA damage when 
comparing Gilbert with control group after splitting data in men and women. 
Mean values of single– and double-strand breaks and FPG- sensitive sites were 
slightly, non-significantly higher in subjects with Gilbert’s syndrome among both 
sexes. ENDO III- sensitive sites were lower in the Gilbert group in men and 
women (see Figure 20). 
The mean in strand breaks, FPG- and ENDO III- sensitive sites was generally 
lower in women compared to men in both groups Gilbert and controls (see also 
Figure 20). 
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Figure 20: DNA damage in Gilbert’s Syndrome and control and gender 
The results summarised in Table 9 demonstrate the impact of gender on DNA 
damage in the whole study population.  
Table 9:  Impact of gender on DNA damage in the whole study population 
 Male Female pValue 
Number 69 29  
% DNA in tail Lysis 5.3 ± 1.21 4.6 ± 1.14 0.005 
% DNA in tail FPG 5.1 ± 2.94 4.4 ± 2.31 0.283 
% DNA in tail ENDO III 2.2 ± 1.21 2.0 ±  1.35 0.494 
Women had significantly lower strand breaks in comparison to men. Women 
showed 15.2 % (p < 0.01) lower mean DNA damage for lysis, 15.9 % lower 
FPG- sensitive sites and 10 % lower mean ENDO III- sensitive sites (see Figure 
21).  
Higher levels of strand breaks in men were possibly caused by lower mean 
levels of vitamin B12 (cobalamin) in men which showed protective effect towards 
DNA damage (see chapter 4.1.3.6). Furthermore men had higher mean levels 
of uric acid which showed a correlation with single- and double-strand breaks 
(see chapter 4.1.3.5). 
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Figure 21: Impact of gender on DNA damage in the whole study population, ** p<0.01 
The difference in background levels of DNA damage between men and women 
is not clear yet. Studies which evaluated the difference between both sexes 
show conflicting results. 
The results of the current study are in agreement with the result of a large 
cross-sectional study which reported that smoking increases DNA damage and 
that this effect is more significant in men compared to women [BETTI et al., 
1994]. In the following year Betti studied DNA damage in an extended study 
population and it was shown that mean comet length in males was higher 
compared to women at borderline (p = 0.053) [BETTI et al., 1995]. 
Mendoza-Núñez et al., showed that elderly male had a 2-fold higher probability 
of having DNA damage compared to female [MENDOZA-NÚÑEZ et al., 2001]. 
In the study of Bajpayee et al., basic DNA damage in a young (age: 20-30) and 
healthy Indian male and female population illustrated that men had statistical 
significant higher level of DNA damage after lysis in comparison to females 
(Males % DNA in tail: 10.2 ± 2.96; Females % DNA in tail: 9.40 ± 2.83) 
[BAJPAYEE et al., 2002]. 
A very recent study with healthy individuals showed no significant difference 
among gender and strand breaks [DIXIT 2011]. Kazimírová who compared 
genomic damage in healthy non-vegetarians and vegetarians reported no sex 
difference in levels of DNA damage (strand breaks, FPG- and ENDO III-
 sensitive sites) [KAZIMÍROVÁ et al., 2006].  
** 
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4.1.3.3. Albumin 
 
Figure 22: Correlation between Albumin and DNA damage (lysis) 
Albumin correlated with single- and double-strand breaks in the whole study 
population although the correlation was not significant (see Figure 22). 
A highly significant correlation between the concentration of albumin and DNA 
damage detected by lysis was observed in women < 30 years (r= -0.565; p= 
0.018). 
Albumin showed no correlation with oxidised DNA bases (FPG- and ENDO III- 
sensitive sites). 
The major physiological function of albumin is the transport of lipid soluble 
substances such as fatty acids, hormones, cholesterol, bile pigments, drugs and 
metals [CANDIANO et al., 2009; ROCHE et al., 2008]. 
While several endogenous antioxidative systems are mainly active within the 
intracellular environment, albumin is considered as the most abundant protein in 
human plasma providing a major part of total antioxidative properties in the 
extracellular space [CANDIANO et al., 2009; ROCHE et al., 2008]. Low albumin 
levels are an important risk factor for all-cause and vascular mortality especially 
in men [GRIMM et al., 2009]. The strong antioxidant character of albumin can 
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possibly be explained by its ligand binding capacities which can assume 
different conformation and thus adapt the form of many different ligands 
[ROCHE et al., 2008].  
Free transition metals Cu (II) and Fe (II) are involved in the generation of the 
highly reactive hydroxyl radical OH*- via the Fenton’s reaction from H2O2.  
Albumin binds copper tightly and iron with low affinity. It was shown that the 
addition of albumin to a H2O2/ Fe2+/ EDTA-catalysed oxidation system is able to 
reduce the consumption of H2O2 and thus the formation of hydroxyl radical, 
which at the same time decelerates free radical attack of other biomolecules 
[KOCHA et al., 1997]. It was shown by the same study that copper bound to 
albumin can still lead to the formation of OH*- [KOCHA et al., 1997]. Although it 
is suggested that formed OH*- are mostly directed to albumin, preventing more 
important biomolecules from oxidative damage. Additionally, metals bound to 
albumin are less susceptible to take part in the Fenton reaction [ROCHE et al., 
2008]. 
4.1.3.4. Creatinine  
 
Figure 23: Correlation between Creatinine and DNA damage 
Significant correlations were observed between creatinine levels and strand 
breaks detected by lysis in the whole study population (r= 0.298; p= 0.003) (see 
Figure 23). 
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This correlation was even stronger in younger subjects < 30 years (r= 0.362; 
p= 0.004). In women there was also a weak correlation although not significant 
(r= 0.308; p= 0.104).  
Creatinine levels and FPG-sensitive sites also correlated non-significantly in 
women (r= 0.336; p= 0.075) 
There was no correlation found between creatinine concentration and ENDO III- 
sensitive sites.  
The results are in agreement with the study of Stoyanova et al., who measured 
the background level of genetic damage in 253 patients with chronic renal 
failure (CRF). In this study a positive correlation between creatinine levels and 
FPG- sensitive sites was found [STOYANOVA et al., 2010]. 
Stopper and co-workers also measured the impact of chronic renal failure on 
oxidative DNA damage and found that serum creatinine levels over 6 mg/dl led 
to an increase in oxidative DNA damage [STOPPER et al., 2001]. 
Baseline serum creatinine levels were shown to be related to increased risk of 
prostate cancer [WEINSTEIN et al., 2009]. Creatinine is an indicator for renal 
function and glomerular filtration. Thus, diminished renal function or renal 
disease leads to increased creatinine levels [WEINSTEIN et al., 2009].  
The mean concentrations of creatinine in the study population were 0.98 mg/dl 
which is in the normal range (0.6-1.36 mg/dl). Due to decreased muscle mass, 
women generally have lower concentrations of creatinine [DORMANN et al., 
2009].  
Higher levels of creatinine showed correspondence with increased DNA 
damage in women indicating that increased creatinine concentrations might 
have negative impact on DNA stability.  
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4.1.3.5. Uric acid                                        
 
Figure 24: Correlation between Uric acid and DNA damage 
A highly significant and strong correlation was observed between Uric acid 
levels and DNA damage (lysis) in the whole study population (r= 0.426; p = 
0.000) (see Figure 24). 
This correlation was highly significant in men (r= 0.411; p= 0.000) and men < 30 
years (r = 0.444; p= 0.003).  
The strongest correlation was observed between Uric acid levels and lysis in 
young subjects < 30 years (r= 0.533; p= 0.000). 
Another correlation, weak but significant, was found between Uric acid and 
FPG- sensitive sites in the whole study population (r= 0.213; p= 0.035). 
There was no significant correlation found, between uric acid levels and ENDO 
III- sensitive sites.  
Uric acid (UA) is produced by the breakdown of purine nucleotides, which are 
principal constituents of cellular energy stores ATP and also DNA and RNA. In 
most mammals, urate is further metabolised to allantoin with the aid of Uricase 
which leads to substantially reduced UA levels in plasma [RUGGIERO et al., 
2006]. In humans the enzyme Uricase is not expressed leading to increased 
levels of UA. Ames suggested, that elevated levels of UA can protect humans 
from aging and cancer due to its strong antioxidant potential [AMES et al., 
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1981]. Nowadays, it is still controversial whether high UA levels can supress 
increased oxidative stress and oxidative stress related disease [ROGGIERO et 
al., 2006]. Several studies indicate that high levels of UA are a risk factor for 
increased cardiovascular and all-cause mortality [NISKANEN et al., 2004] and 
also a risk factor for cancer [KOLONEL et al., 1994]. It was suggested that there 
is a positive relation between uric acid and pro inflammatory markers which are 
elevated in many chronic diseases especially in older people [RUGGIERO et 
al., 2006]. It was also found that cancer-patients show elevated levels of uric 
acid caused by malignancy, which is characterised by high proliferation rate of 
diseased tissue and increased nucleic acid turnover [STRASAK et al., 2008]. 
 
Figure 25: Distribution of uric acid levels in men and women 
In the distribution plot it is clearly illustrated that men of the study group had 
higher ranges of uric acid levels (µmol/L) (5.9 ± 0.90) than females (4.5 ± 0.74). 
The values are consistent with the measurements of Choi and co-workers 
[CHOI et al., 2005]. Higher mean levels of uric acid in men might be an 
explanation for the increased levels of single- and double strand breaks in men 
compared to women (see chapter 4.1.3.2). 
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4.1.3.6. Vitamin B12 (cobalamin) 
Vitamin B 12 is known to play a crucial role in DNA metabolism. In order to 
examine whether vitamin B12 has an impact on values of strand breaks and/or 
modified DNA bases, the study population was divided into three similar groups 
with different vitamin B12 concentrations (see Table 10). 
Table 10:  DNA damage and Vitamin B12 tertiles 
 Tertile 1: 
0.5- 1.4 
pM/L 
Tertile 2: 
1.4- 2.0 
pM/L 
Tertile 3: 
2.0- 4.0 
pM/L 
pValue 
Number 37 24 35  
% DNA in tail Lysis 5.8 ± 0.80 5.0 ± 1.35 4.5 ± 1.20 0.000 
% DNA in tail FPG 6.0 ± 3.18 5.3 ± 2.60 3.5 ± 1.74 0.000 
% DNA in tail ENDO III 2.5 ± 1.46 2.0 ± 1.11 2.1 ± 1.10 0.284 
 
There was a strong inverse relation between levels of Vitamin B12 measured in 
erythrocytes and strand breaks and FPG- sensitive sites. Any increase in 
Vitamin B12 concentration was followed by reduced mean levels of strand 
breaks and FPG- sensitive sites.  Higher levels of Vitamin B12 also reduced 
ENDO III- sensitive sites although lacking statistical significance. 
   
Figure 26: DNA damage and vitamin B12 tertiles 
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Figure 27: Correlation between Vitamin B12 in Erythrocytes and DNA damage 
Vitamin B12 correlated strongly and highly significant with strand breaks (lysis) in 
the whole study population (r= -0.452; p= 0.000) and in men (r= -0.511; 
p= 0.000). The correlation was also observed in both age groups (< 30 years: 
r= -0.464; p= 0.000; > 30 years: r= -0.420; p= 0.012).  
Moreover, a highly significant correlation between B12 and FPG-sensitive sites 
in the whole study population was observed (r= -0.397; p= 0.000). This 
correlation was also observed in both genders (men: r= -0.384; p= 0.001; 
women: r= -0.422; p= 0.032) and in both age groups (< 30 years: r= -0.436; 
p= 0.001; > 30 years: r= -0.391; p= 0.020). A very strong and significant 
correlation was observed in women > 30 years (r= -0.611; p= 0.046).  
There were no significant correlations observed between B12 and ENDO III-
sensitive sites.  
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Figure 28: Distribution of erythrocyte (red blood cell) cobalamin in men and women 
The mean level of cobalamin in red blood cells in the study population was 1.9 ± 
0.65 pM/l. In men levels were slightly lower (1.8 ± 0.64) compared to women 
(1.9 ± 0.68). Lower levels of cobalamin in men may be an explanation for the 
higher values of DNA damage that was observed in men in comparison to 
women (see chapter 4.1.3.2). 
Summarising the results, vitamin B12 showed a protective effect towards DNA 
damage. Thus, in our study vitamin B12 was able to minimise the formation of 
strand breaks but also oxidation of DNA bases especially purines.  
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Figure 29: Pathway of folic acid and Vitamin B12 [Fenech, 2001] 
Together with folic acid, vitamin B12 plays a crucial role in DNA metabolism and 
DNA repair. It is required for the synthesis of S-adenosyl methionine (SAM), 
which is the common methyl donor required for the maintenance of methylation 
patterns in DNA (see Figure 29). Vitamin B12 is a water-soluble essential 
vitamin, thus mammals are unable to synthesise Vitamin B12 de novo. The 
vitamin must be obtained from the diet or from microbial breakdown in the gut 
[DUTHIE, 1999].  
Low concentrations of B12 and folic acid lead to deficient methylation of uracil to 
thymidine and subsequent incorporation of uracil into DNA [FENECH, 2001]. 
Excessive incorporation of uracil into DNA might cause point mutation, single- 
and double-strand breaks, chromosome breakage and micronucleus formation 
[FENECH, 2001]. Both folate and B12 deficiency independently or together have 
been shown to cause chromosome damage and micronucleus formation in vivo 
in humans [KAZIMÍROVÁ et al., 2006]. 
A strong negative correlation between concentrations of vitamin B12 and 
oxidative DNA damage in peripheral mononucleated cells was found. Most 
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studies did not detect an effect of Vitamin B12 level on markers of oxidative DNA 
damage.  
Milic and co-workers failed to detect an effect of Vitamin B12 and folic acid levels 
on DNA damage in terms of strand breaks and alkali labile sites [MILIC et al., 
2010]. Also the study of Zijno et al., 2003 tail moment was examined by comet 
assay and was not affected neither by Vitamin B12 nor folic acid [ZIJNO, 2003].  
A more frequent lesion of DNA caused by folate or Vitamin B12 deficiency is the 
uracil incorporation (UrMis) into DNA instead of thymidine. Thus, studies using 
a modified version of comet assay by inclusion of the enzyme uracil glycosylase 
show more clear results concerning association between the two essential 
vitamins and their role in DNA metabolism. 
4.1.3.7. Folic acid 
Additionally the study population was divided into three groups of different folic 
acid levels. Table 11 summarises mean values of DNA damage for red cell 
folate within the three groups. 
Table 11:  DNA damage and red cell folate tertiles 
  Tertile 1: 
38.90- 
72.80 
ng/mL 
Tertile 2: 
74.10- 
152.40 ng/ mL 
Tertile 3: 
157.10- 
510.40 ng/mL 
pValue 
Number 31 32 33  
% DNA in tail Lysis 5.1 ± 1.55 5.3 ± 1.01 5.0  ± 1.18 0.644 
% DNA in tail FPG 4.3 ± 2.95 4.8  ± 2.13 5.8  ± 3.19 0.294 
% DNA in tail ENDO III 1.9  ± 1.05 2.3  ± 1.34 2.4  ± 1.37 0.097 
 
Results show that there was no significant difference in mean DNA damage 
between the three different folic acid concentrations.                
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FPG- and ENDO III- sensitive sites tended to increase with higher red cell folate 
concentration but differences in DNA damage were not significant. 
    
Figure 30: Correlation between red cell folate and DNA damage 
Correlations were observed between folic acid in erythrocytes and DNA 
damage especially in women (see Figure 30).  
In women ≥ 30 years a positive correlation between red cell folate and strand 
breaks (r= 0.427; p= 0.219) was observed but results were not significant. On 
the contrary in women < 30 years a significant negative correlation was found 
between red cell folate and strand breaks (r= -0.524; p= 0.045). 
Correlations were found between folic acid and FPG- sensitive sites in women, 
however statistical significance was lacking (r= 0.345; p= 0.091). This 
correlation was even stronger and also significant in women ≥ 30 years (r= 
0.648; p= 0.043).  
Folic acid also correlated with ENDO III- sensitive sites in women generally 
(r= 0.469; p= 0.024) and strong correlation was found in women ≥ 30 years (r= 
0.793; p= 0.019). 
To sum up the results, folic acid mainly had impact on DNA damage in females. 
It was found that folic acid influenced especially oxidation damage in terms of 
FPG- and ENDO III- sensitive sites. With regard to strand breaks results are not 
clear; in women ≥ 30 years folic acid increased DNA damage whereas in 
women < 30 it reduced the amount of strand breaks in DNA. 
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In the study of Duthie and Hawdon folate supplementation did not show an 
effect on level of oxidised pyrimidines in vitro, thus suggesting that folate 
deficiency increases uracil miscorporation specifically and does not influence 
oxidative DNA damage [DUTHIE and HAWDON 1998].  
On the other hand in a case-control study red cell folate did correlate negatively 
with FPG- sensitive sites [HUSSEIN et al., 2005]. Also Courtemanche and co-
workers showed that folate deficiency leads to increased DNA damage in 
primary lymphocytes [COURTEMANCHE et al., 2004]. 
It was proposed by Duthie that DNA damage occurs at folic acid concentrations, 
which are routinely measured in plasma from the human population [DUTHIE 
and HAWDON 1998]. 
 
Figure 31: Distribution of red cell folate in men and women 
The distribution plot shows that the study subjects had mean red cell folate 
concentrations of 139.8 ng/ml. In females, average folate concentrations were 
slightly higher 159.1 ± 139.33 in comparison to men 132.4 ± 93.02.  
The recommended daily intake of micronutrients may not be optimal for the 
purpose of protection from genomic damage. According to Fenech, higher 
intake of folic acid than RDI (recommended dietary intakes) is required for the 
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protection against DNA damage. In general, 464 ng/ml red cell folate 
concentrations were shown to correspond to minimisation of DNA damage 
[FENECH, 2001]. 
The average folate concentration in the study population was probably too low 
for minimisation of DNA damage. Therefore the increased strand breaks 
detected by lysis in women ≥ 30 years might be linked to folate concentration 
due to increased uracil misincorporation and nicks in the DNA which occur 
during the repair process.  
4.1.3.8. Correlations within DNA damage endpoints 
 
Figure 32: Correlation between DNA damage endpoints lysis and FPG- sensitive sites 
There were strong correlations observed among the individual DNA damage 
endpoints. For instance lysis and FPG- sensitive sites, correlated highly 
significant in the whole study population (r= 0.378; p= 0.000), in men (r= 0. 376; 
p= 0.044) and women (r= 0.362; p= 0.002) (see Figure 32). Lysis and FPG-
 sensitive sites also correlated in people < 30 years (r= 0.382; p= 0.002) and 
people ≥ 30 years (r = 0.485; p= 0.002). The results indicate that higher levels 
of strand breaks detected by lysis are accompanied by higher values of FPG-
sensitive sites (oxidised purines). Up to now, no studies investigated the 
correlation between oxidised bases and strand breaks. 
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4.1.4. Linear regression 
A stepwise linear regression model was made in order to estimate how much of 
DNA damage was explained by independent variables that were considered. 
Included variables were: Albumin, uric acid, creatinine, age, unconjugated 
serum bilirubin, vitamin C, glutathione, folic acid in erythrocytes, vitamin B12 in 
erythrocytes and BMI. 
4.1.4.1. Lysis 
Table 12:  Linear regression model Lysis 
Test subjects (n) Predictors Adjusted R2 pValue 
All test sujects (92) Cobalamin 
Uric acid 
Albumin 
Glutathion 
Creatinine 
0.206 
0.332 
0.387 
0.411 
0.434 
0.000 
0.000 
0.004 
0.034 
0.035 
Men (67) Cobalamin 
Uric acid 
Glutathion 
Albumin 
0.255 
0.370 
0.436 
0.466 
0.000 
0.000 
0.000 
0.037 
Women (25) Albumin 
Vitamin C 
0.142 
0.261 
0.036 
0.041 
< 30 years (58) Uric acid 
Glutathion 
Cobalamin 
Vitamin C 
Albumin 
Creatinine 
0.270 
0.425 
0.495 
0.540 
0.594 
0.622 
0.000 
0.000 
0.005 
0.016 
0.006 
0.034 
≥ 30 years  (34) Cobalamin 
BMI 
0.168 
0.257 
0.009 
0.036 
 
74 
 
Table 12  summarises the results for the stepwise linear regression model for 
lysis. In the whole study population 43.4% of DNA was explained by cobalamin, 
uric acid, albumin, glutathione and creatinine whereby cobalamin, uric acid and 
albumin already explained 38,7 % of the DNA damage.  
In men DNA damage was mainly influenced by cobalamin, uric acid, glutathione 
and albumin which summed up to a total of 46.6 % of DNA damage.  
In women albumin and vitamin C had the greatest impact on DNA damage 
explaining 26.1 % of DNA damage.  
According the two age groups, in the younger subjects (< 30 years) DNA 
damage was mainly influenced by the variables uric acid, glutathione, 
cobalamin, vitamin C, albumin and creatinine which together explained 62.2 % 
of DNA damage. In older subjects (≥ 30 years) cobalamin and BMI explained 
25.7 % of DNA damage.  
Summarising the results of the linear regression model it can be seen, that all 
together cobalamin, uric acid and albumin had the greatest impact on single- 
and double-strand breaks detected by lysis. As already discussed in earlier 
chapters cobalamin and albumin showed a correspondence with DNA damage 
and reduced it whereas uric acid rather increased the level of DNA damage. 
4.1.4.2. FPG 
Table 13:  Linear regression model for FPG 
Test subjects (n) Predictors Adjusted R2 pValue 
All test subjects (92) Cobalamin 
Folic acid 
0.149 
0.179 
0.000 
0.043 
Men (67) Cobalamin 0.132 0.001 
Women (25) Cobalamin 
Creatinine 
0.156 
0.268 
0.029 
0.045 
< 30 years (58) Cobalamin 0.175 0.001 
≥ 30 years  (34) Cobalamin 0.145 0.015 
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In the whole study population the greatest impact on DNA damage in terms of 
FPG- sensitive sites was shown by cobalamin and folic acid which together 
explained 17.9% of DNA damage.  
In men, FPG- sensitive sites were mainly influenced by cobalamin by 13.2% 
and in women cobalamin and creatinine had the greatest impact on DNA 
damage explaining 26.8% of total FPG- sensitive sites.  
In the younger subjects (< 30 years) cobalamin explained 17.5% of oxidised 
purines and in older subjects (≥ 30years) cobalamin explained 14.5% of DNA 
damage.  
To sum up cobalamin showed the greatest effect on oxidised purines in the 
whole study population also after stratification for sex and age. The results from 
linear regression model indicate that cobalamin plays a crucial role when it 
comes to oxidative stress and DNA damage although the mechanism is still not 
known.  
4.1.4.3. ENDO III 
Table 14:  Linear regression model for ENDO III 
Test subjects (n) Predictors Adjusted R2 pValue 
All test subjects (85) No model found - - 
Men (65) No model found - - 
Women (23) Folic acid 
Glutathione 
Vitamin C 
0.183 
0.366 
0.501 
0.024 
0.015 
0.020 
< 30 years (56) No model found - - 
≥ 30 years  (32) No model found - - 
 
There were only models found explaining DNA damage in women. In women 
50.1% of ENDO III- sensitive sites were explained by the variables folic acid, 
glutathione and vitamin C.  
These results indicate that folic acid but also glutathione and vitamin C have an 
impact on DNA damage in terms of oxidised pyrimidines in women.  
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5. Conclusion 
The framework of the present work aimed at exploring the antigenotoxic effect 
of bilirubin. Furthermore it was evaluated whether subjects with Gilbert’s 
syndrome (mild hyperbilirubnemia) are better protected against oxidative stress 
and oxidative stress mediated DNA damage. 
In order to assess the antigenotoxic properties of bilirubin the amount of DNA 
damage in peripheral blood mononucleated cells (PBMCs) in subjects with 
Gilbert’s syndrome and control was analysed. As a method the comet assay 
was conducted which allows the measurement strand breaks in DNA efficiently. 
Moreover, oxidative modified DNA bases were analysed by inclusion of lesion-
specific enzymes; which give more specific information about oxidative stress 
related DNA damage. 
Due to the strong reported antioxidative capacities of bilirubin an inverse 
relation between bilirubin levels and DNA damage was expected. In fact the 
hypothesis could not be confirmed, as there were no significant differences in 
DNA damage between GS and control. Furthermore, there were no differences 
in DNA damage after subdividing the study population in 3 similar groups of 
different bilirubin levels (bilirubin tertiles). 
However the experiment delivered other findings. Various endogenous factors 
had a significant impact on DNA damage. Albumin for instance significantly 
decreased strand breaks in young women < 30 years, indicating that albumin 
might have an antigenotoxic potential especially in young women. There was a 
significant positive correlation between uric acid and strand breaks mainly in 
men. Thus, uric acid induced DNA damage and further creatinine correlated 
positively with DNA damage.  
Regarding gender, it was observed that women show significantly lower 
amounts of single- and double- strand breaks compared to men. Higher DNA 
damage in men might be explained by higher uric acid levels which showed 
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prooxidative effects and lower levels of cobalamin which on the contrary 
showed protective effect towards DNA damage.  
Age on the other hand showed no significant impact on DNA damage, when 
measured with this assay. 
There were also dietary factors which influenced DNA stability significantly. It is 
necessary to mention the essential water-soluble Vitamin B12 (cobalamin). 
Individuals with high levels of vitamin B12 showed significantly lower DNA 
damage in comparison to people with low levels of vitamin B12 levels. Also folic 
acid showed an impact on DNA damage although results are controversial. 
Folic acid partly induced DNA damage but also reduced DNA damage 
depending on the study population analysed.  
In conclusion there were various factors which influenced biomarkers of 
oxidative DNA damage detected by the comet assay. Such influencing factors 
were gender; endogenous compounds mainly albumin, uric acid and creatinine 
but also dietary substances like vitamin B12 and folic acid. However, we were 
not able to validate the antioxidant capabilities of bilirubin towards at DNA 
damage or protection against it in subjects with GS. Further investigations are 
necessary to get more insight into the potent antioxidant activities of bilirubin at 
DNA level.  
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6. Summary 
This present work was carried out at the Department of Nutritional Sciences at 
the University of Vienna and was funded by the FWF-Austria Science Fund. 
The major objective of this work was to evaluate the antigenotoxic potential of 
unconjugated bilirubin in a large human case-control study. 
Therefore persons with mild elevated levels of unconjugated bilirubin (Gilbert’s 
syndrome, n= 45) as well as individuals with normal bilirubin levels (control, n= 
39) were recruited from the general population. According to their level of 
unconjugated bilirubin, which was measured by HPLC, subjects were allocated 
to the Gilbert or control group. Inclusion and exclusion criteria were checked by 
a blood sample and questionnaires beforehand. Subjects were recruited by 
information sheets and advertisements in public buildings and internet 
platforms. The study was approved by the Human Ethics Research Committee 
of the general hospital, Vienna (Ref. No.: 274/2010).  
To measure DNA damage biomarkers a commonly applied method the “Comet 
assay” was conducted. In order to attain the level of oxidative DNA damage 
additionally specific repair enzymes were included (ENDO III and FPG). 
Bilirubin has already been reported to have antioxidant properties. As a 
consequence it was hypothesised that individuals with elevated bilirubin 
concentrations show less DNA damage than controls. However, the hypothesis 
could not be confirmed as there were no differences concerning DNA damage 
in Gilbert and control.  
In particular it was observed that other endogenous factors showed significant 
impact on DNA damage, but bilirubin did not. Serum albumin showed an 
inverse relation with DNA damage, whereas uric acid and creatinine induced 
DNA damage and subsequently showed prooxidant effects. Additionally a 
strong negative correlation was found between vitamin B12 and DNA damage. In 
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respect of gender, women showed significantly lower amounts of DNA strand 
breaks compared to men. Age showed no influence on DNA damage. 
So far, there is only very little information available on the impact of elevated 
bilirubin levels on DNA damage. In order to investigate the beneficial function of 
bilirubin at DNA level further research is required, focusing more on risk groups 
of oxidative stress. 
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7. Zusammenfassung 
Die vorliegende Arbeit wurde am Institut für Ernährungswissenschaften  an der 
Universität Wien durchgeführt und vom Österreichischen Wissenschaftsfond 
unterstützt. Hauptziel dieser Arbeit war es das antigenotoxische Potential von 
unkonjugiertem Bilirubin in einer großen Fall-Kontroll Studie zu erfassen.  
Dafür wurden Personen mit leicht erhöhtem unkonjugiertem Bilirubin (Gilbert’s 
syndrom, n= 45) sowie Personen mit normalem Bilirubinspiegel (Kontrolle, 
n= 39) von der allgemeinen Bevölkerung rekrutiert. Die Probanden wurden je 
nach unkonjugiertem Bilirubinspiegel welcher mittels HPLC erfasst wurde zu 
der Gruppe Gilbert’s syndrom oder Kontrolle zugeordnet. Ein- und 
Ausschlusskriterien wurden mit Hilfe einer Blutprobe sowie durch Fragebögen 
überprüft. Die Rekrutierung der Testpersonen erfolgte mit Hilfe von Merkblättern 
und Anzeigen in öffentlichen Gebäuden sowie Internetplattformen. Die Studie 
wurde von der Ethikkommission des Allgemeinen Krankenhauses der Stadt 
Wien genehmigt (Nr.: 274/2010). 
Zur  Messung von Biomarkern von DNA-Schäden wurde eine häufig 
verwendete Methode nämlich der „Comet assay“ eingesetzt. Zusätzlich wurden 
Reparaturenzyme miteinbezogen, um das Niveau von oxidativen DNA-Schäden 
zu ermitteln.  
Bilirubin konnte in verschiedenen Studien zeigen, dass es antioxidative 
Eigenschaften besitzt. Demzufolge wurde die Hypothese aufgestellt, dass 
Personen mit erhöhtem Bilirubinspiegel geringere DNA-Schäden aufweisen als 
die Kontrollgruppe. Diese Hypothese konnte jedoch nicht bestätigt werden, da 
es keine Unterschiede in Bezug auf DNA-Schäden zwischen Gilbert und 
Kontrolle gab.  
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Im Gegensatz zu Bilirubin wurde jedoch gezeigt, dass andere endogene 
Faktoren erheblichen Einfluss auf DNA-Schäden aufwiesen. Einerseits zeigte 
Serumalbumin eine inverse Beziehung mit DNA-Schäden vor allem bei jungen 
Frauen. Andererseits induzierten Harnsäure und Kreatinin DNA-Schäden und 
wirkten somit prooxidativ.  
Eine starke negative Korrelation wurde zwischen DNA-Schäden und Vitamin 
B12 beobachtet. In Bezug auf das Geschlecht, zeigten Frauen signifikant 
geringere DNA-Schäden als Männer. Das Alter hingegen hatte keinen Einfluss 
auf die DNA-Stabilität.  
Bis zum jetzigen Zeitpunkt gibt es sehr wenig Information über den Einfluss von 
Bilirubin auf die DNA-Stabilität in Personen mit GS. Um die Schutzfunktion von 
Bilirubin auf die DNA genauer zu untersuchen sind weitere Forschungsarbeiten 
erforderlich, dabei sollte man sich auf spezielle Risikogruppen fokussieren. 
83 
 
8. References 
Ahlfons CE, Wennberg RP, Ostrow JD, Tiribelli C. (2009). Unbound (Free) 
Bilirubin: Improving the Paradigm for Evaluating Neonatal Jaundice. Clinical 
Chemistry 55 (7): 1288 – 1299 
Ames BN, Cathcart R, Schwiers E, Hochstein P. (1981). Uric acid provides an 
antioxidant defense in humans against oxidant- and radical-caused aging and 
cancer: a hypothesis.PNAS 78 (1): 6858-6862 
Asad SF, Singh S, Ahmad A, Hadi SM. (2000). Inhibition of L-DOPA-Cu(II)-
mediated DNA cleavage by bilirubin Toxicology in Vitro 14: 401 – 404  
Asad SF, Singh S, Ahmad A, Hadi SM. (2002). Bilirubin/biliverdin-Cu(II) induced 
DNA breakage; reaction mechanism and biological significance. Toxicology 
Letters 131: 181 – 189 
Bajpayee M, Dhawan A, Parmar D, Pandey AK, Mathur N, Seth PK. (2002). 
Gender-related differences in basal DNA damage in lymphocytes of a healthy 
Indian population using the alkaline Comet assay. Mutation Research 520: 83 – 
91 
Baranano DE, Rao M, Ferris CD, Snyder SH. (2002). Biliverdin reductase: a 
major physiologic cytoprotectant. Proceedings of the National Academy of 
Sciences 99: 16093 – 16098 
Bernhard K, Ritzel G, Steiner KU. (1954). Über eine biologische Bedeutung der 
Gallenfarbstoffe. Bilirubin und Biliverdin als Antioxydantien für das Vitamin A 
und die essentiellen Fettsäuren. Helvetia Chimica Acta 37 (1): 306 – 313 
Betti C, Davini T, Gianessi L, Loprieno N Barale R. (1994). Microgel 
electrophoresis assay (comet test) and SCE analysis in human lymphocytes 
from 100 normal subjects. Mutation Research 307: 323–333 
84 
 
Betti C, Davini T, Giannessi L, Loprieno N, Barale R. (1995). Comparative 
studies by comet test and SCE analysis in human lymphocytes from 200 
healthy subjects. Mutation Research 343 (4): 201-207 
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout 
D, Tytgat GNJ, Jansen PLM, Elferink RPJ, Chowdhury NR. (1995). The genetic 
basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in 
Gilbert’s syndrome. The new England Journal of Medicine 333 (18): 1171 – 
1175 
Botto N, Masetti S, Petrozzi L, Vassalle C, Manfredi S, Biagini A, Andreassi 
MG. (2002). Elevated levels of oxidative DNA damage in patients with coronary 
artery disease. Coronary Artery Disease 13(5): 269-74 
Bulmer AC, Ried K, Coombes JS, Blanchfield JT, Toth I., Wagner KH. (2007). 
The anti-mutagenic and antioxidant effects of bile pigments in the Ames 
Salmonella test. Mutation Research 629: 122 – 132 
Bulmer AC. (2008). The efficiacy of bile pigment supplementation In vivo and in 
vitro. (Dissertation)  
Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. (2008a). Improved 
resistance to serum oxidation in Gilbert’s Syndrome: A mechanism for 
cardiovascular protection. Atherosclerosis 199: 390 – 396  
Bulmer AC, Ried K, Blanchfield JT, Wagner KH. (2008b). The anti-mutagenic 
properties of bile pigments. Mutation Research 658: 28 – 41 
Candiano G, Petretto A, Bruschi M, Santucci L, Dimuccio V, Prunotto M, 
Gusmano R, Urbani A, Ghiggeri GM (2009) The oxido-redox potential of 
albumin Methodological approach and relevance to human diseases. Journal of 
Proteomics 73: 188 – 195 
85 
 
Choi HK, Liu S, Curhan G. (2005). Intake of purine-rich foods, protein and dairy 
products and relationship to serum levels of uric acid: The Third National Health 
and Nutrition Examination Survey. Arthitis & Rheumatism 52 (1): 283-289  
Collins AR, Dusinska M, Franklin M, Somorovska M, Petrovska H, Duthie S, 
Fillion L, Panayiotidis M, Raslova K, Vaughan N. (1997). Comet Assay in 
Human Biomontoring Studies: Reliability, Validation and Applications. 
Environmental and Molecular Mutagenesis 30: 139 – 146 
Collins AR, Dušinská M, Horská. (2001). A Detection of alkylation damage in 
human lymphocyte DNA with the comet assay. Nature 48 (3): 611-614. 
Collins AR. (2004). The Comet Assay for the DNA Damage and Repair. 
Principles, Applications and Limitations. Molecular Biotechnology 26: 249 – 261 
Collins AR, Oscoz AA, Brunborg G, Gaivao, Giovannelli L, Kruszewski M, Smith 
CC, Stetina R. (2008). REVIEW The Comet assay: topical issues. Mutagenesis 
23: 143 – 151 
Collins AR. (2009). Investigating oxidative DNA damage and its repair using the 
comet assay. Mutation Research 681: 24 – 32 
Courtemanche C, Huang AC, Elson-Schwab I, Kerry N, Ng BY, Ames BN. 
(2004). Folate deficiency and ionizing radiation cause DNA breaks in primary 
human lymphocytes: a comparison. The FASEB Journal: official publication of 
the Federation of American Societies for Experimental Biology 18(1): 209-11 
David SS, O’Shea VL, Kundu S. (2007). REVIEW Base-excision repair of 
oxidative DNA damage. Nature 447: 941-950 
Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. (1995). 
Hyperbilirubinemia results in reduced oxidative injury in neonatal gunn rats 
exposed to hyperoxia. Free Radical Biology & Medicine 19 (4): 395 – 404 
86 
 
Dixit AK, Aurun N. (2011). Assessment of basal DNA damage in Normal and 
Healthy Young Individuals by comet assay. Journal of Bioscience and 
Technology 2(2): 247-257 
Dhawan A, Bajpayee M, Pandey AK, Parmar D. Protocol for the single cell gel 
electrophoresis / Comet assay for rapid genotoxicity assessment. Development 
Toxicology Division. Industrial Toxicology Research Centre. 
Dhawan A, Bajpayee M, Parmar D. (2009). Comet Assay: a reliable tool for the 
assessment of DNA damage in different models. Cell biology and toxicology 25: 
5 – 32 
Dormann AJ, Luley C, Heer C. (2009). Laborwerte. 5te Auflage. Verlag Urban 
und Fischer, München: 106 
Dröge W. (2002). Free Radicals in the Physiological Control of Cell Function. 
Physiological Reviews 82: 47 – 95 
Dusinská M, Dzupinková Z, Wsólová L, Harrington V, Collins AR. (2006). 
Possible involvement of XPA in repair of oxidative DNA damage deduced from 
analysis of damage, repair and genotype in a human population study. 
Mutagenesis 21 (3): 205-211 
Dusinska M, Collins AR. (2008). REVIEW. The Comet assay in human 
biomonitoring: gene-environment interactions. Mutagenesis 23 (3): 191 – 205 
Duthie SJ, Hawdon A. (1998). DNA instability (strand breakage, uracil 
misincorporation, and defective repair) is increased by folic acid depletion in 
human lymphocytes in vitro. The FASEB journal: official publication of the 
Federation of American Societies for Experimental Biology 12 (14): 1491-7 
Duthie SJ (1999) Folic acid deficiency and cancer: mechanisms of DNA 
instability British medical bulletin 55 (3): 578-92 
Elmadfa I, Leitzmann C. (2004). Ernährung des Menschen. 4te korrigierte und 
aktualisierte Auflage. Verlag Eugen Ulmer Stuttgart: 301 – 304 
87 
 
European Standards Committee on Oxidative DNA Damage (ESCODD) (2003). 
Measurement of DNA oxidation in human cells by chromatographic and 
enzymic methods. Free Radical Biology & Medicine 34 (8): 1089 – 1099 
Evans MD, Dizdaroglu M, Cooke MS. (2004). Review Oxidative DNA damage 
and disease: induction repair and significance. Mutation Research 567: 1 – 61 
Fenech M. (2001). The role of folic acid and Vitamin B12 in genomic stability of 
human cells. Mutation research 475(1-2): 57-67 
Frei B, Stocker R, Ames BN. (1988). Antioxidant defenses and lipid peroxidation 
in human blood plasma. Proceedings of the National Academy of Sciences 85: 
9748 – 9752 
Gartung C, Matern S. (1999). Hepatologie: Erkrankungen der Leber. 
Leitsymptome. In: Alexander K, Daniel WG, Diener H-C, Freund M, Köhler H, 
Matern S, Maurer HH, Michel BA, Nowak D, Risler T, Schaffner A, Scherbaum 
WA, Sybrecht GW, Wolfram G, Zeitz M (Hrsg.) THIEMEs Innere Medizin TIM, 
Georg Thieme Verlag Stuttgart-New York: 660 – 666 
GHR- Genetics Home Reference. (2011). Handbook Cells and DNA. URL: 
http://ghr.nlm.nih.gov/handbook.pdf3 (access date: 06.10.2011) 
Gidron Y, Russ Katie, Tissarchondou H, Warner J. (2006). The relation between 
psychological factors and DNA-damage A critical review. Biological Psychology 
72: 291 – 304 
Grimm G, Haslacher H, Kampitsch T, Endler G, Marsik C, Schickbauer T, 
Wagner O, Jilma B. (2009). Sex differences in the association between albumin 
and all-cause and vascular mortality 39 (10): 860-5 
Henriksen T, Hillestrom PR, Poulsen HE, Weimann A. (2009). Automated 
method for the direct analysis of 8-oxo-guanosine and 8-oxo-2´-
deoxyguanosine in human urine using ultraperformance liquid chromatography 
and tandem mass spectrometry. Free Radical Biology & Medicine 47: 629 – 635 
88 
 
Hokamaki J, Kawano H, Yoshimura M, Soejima H, Miyamoto S, Kajiwara I, 
Kojima S, Sakamoto T, Sugiyama S, Hirai N, Shimomura H, Nagayoshi Y, 
Tsujita K, Shioji I, Sasaki S, Ogawa H. (2004). Urinary Biopyrrins Levels Are 
Elevated in Relation to Severity of Heart Failure. Journal of the American 
College of Cardiology 43 (10): 1880 – 1885 
Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, Petersen I. 
(2011). Serum Bilirubin and Risk of Respiratory Disease and Death. Journal of 
American Medical Association JAMA 305 (7): 691 – 697  
Humphreys V, Martin RM, Ratcliffe B, Duthie S, Wood S, Gunnell D, Collins AR. 
(2007). Age-related increases in DNA repair and antioxidant protection: a 
comparison of the Boyd Orr Cohort of elderly subjects with a younger 
population sample. Age and ageing 36 (5): 521-526 
Hussein MMI, McNulty H, Armstrong N, Johnston PG, Spence RAJ, Barnett Y. 
(2005). Investigation of systemic folate status, impact of alcohol intake and 
levels of DNA damage in mononuclear cells of breast cancer patients. British 
journal of cancer 92(8): 1524-30 
Jansen T, Hortmann M,  Oelze M,  Opitz B, Steven, S, Schell, R, Knorr  M, 
Karbach S, Schuhmacher  S, Wenzel P, Münzel T, Daiber A. (2010). 
Conversion of biliverdin to bilirubin by biliverdin reductase contributes to 
endothelial cell protection by heme oxygenase-1-evidence for direct and indirect 
antioxidant actions of bilirubin. Journal of molecular and cellular cardiology 49 
(2): 186-95 
Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, 
Gabazza EG, Adachi Y. (2000). Recent advances in bilirubin metabolism 
research: the molecular mechanism of hepatocyte bilirubin transport and its 
clinical relevance. J. Gastroenterol 35: 659 – 664 
89 
 
Kaplan M, Hammerman C, Maisels MJ. (2003). Bilirubin Genetics for the 
Nongeneticist: Hereditary Defects of Neonatal Bilirubin Conjugation. Pediatrics 
111 (4): 886-893 
Kazimírová A, Barancoková M, Krajcovicová-Kudlácková M, Volkovová K, 
Staruchová M, Valachovicová M, Pauková V, Blazícek P, Wsólová L, Dusinská 
M. (2006). The relationship between micronuclei in human lymphocytes and 
selected micronutrients in vegetarians and non-vegetarians. 611 (1-2): 64-70 
King CM, Bristow-Craig HE, Gillespie ES, Barnett YA. (1997). In vivo 
antioxidant status, DNA damage, mutation and DNA repair capacity in cultured 
lymphocytes from healthy 75- to 80-year-old humans. Mutation research 377(1): 
137-47 
Kocha T, Yamaguchi M, Ohtaki H, Fukuda T, Aoyagi T. (1997). Hydrogen 
peroxide-mediated degradation of protein: different oxidation modes of copper- 
and iron-dependent hydroxyl radicals on the degradation of albumin. 1337 (2): 
319-26 
Kolonel LN, Yoshizawa C, Nomura AM, Stemmermann GN. (1994). 
Relationship of Serum Uric Acid to Cancer Occurrence in a Prospective Male 
Cohort. Cancer epidemiology, biomarkers & prevention 3 (3): 225-8  
Koolman J, Röhm KH. (2002). Stoffwechsel, In:  Tasschenatlas der Biochemie 
3. Auflage 2002, Georg Thieme Verlag Stuttgart 194 – 195 
Krajcovicová-Kudlácková M, Valachovicová M, Pauková V, Dusinská M. (2008). 
Effects of diet and age on oxidative damage products in healthy subjects. 
Physiological research/ Academia Scientiarum Bohemoslovaca 57 (4): 647-651 
Lee K-f, Chung W-y, Benzie IFF. (2010). Urine 8-oxo-7,8-dihydro-2´-
deoxyguanosine (8-oxodG), a specific marker of oxidative stress, suing direct, 
isocratic LC-MS/MS: Method evaluation and application in study of biological 
variation in healthy adults. Clinica Chimica Acta 411: 416 – 422 
90 
 
Maghzal GJ, Leck MC, Collinson E, Li C, Stocker R. (2009). Limited role for the 
Bilirubin-Biliverdin redox amplification cycle in the cellular antioxidant protection 
by biliverdin reductase. The Journal of biological chemistry 284 (43): 29251-
29259 
Maier K-P. (2000). Konjugierte Hyperbilirubinämien. Dubin-Johnson- und 
Rotorsyndrom. In: Hepatitis, Hepatitisfolgen. Praxis der Diagnostik, Therapie 
und Prophylaxe akuter und chronischer Lebererkrankungen. Georg Thieme 
Verlag Stuttgart-New York: 121 – 122 
Maynard S, Schurman SH, Harboe C, De Souza-Pinto NC, Bohr VA. (2009). 
Base excision repair of oxidative DNA damage and association with cancer and 
aging. Carcinogenesis 30 (1): 2-10 
Mc Donagh AF. (2010a). Controversies in bilirubin biochemistry and their 
clinical relevance. Seminars in Fetal& Neonatal Medicine 15: 141 – 147 
Mc Donagh AF. (2010b). The biliverdin-bilirubin antioxidant cycle of cellular 
protection: Missing wheel? Free radical Biology&Medicine 49: 814 – 820 
Mendoza-Núñez VM, Sánchez-Rodríguez MA, Retana-Ugalde R, Vargas-
Guadarrama LA, Altamirano-Lozano MA. (2001). Total antioxidant levels, 
gender, and age as risk factors for DNA damage in lymphocytes of the elderly.  
Mechanism of ageing and development 122 (8): 835-47 
Milic M, Rozgaj R, Kašuba V, Oreščanin V, Balija M, Jukić I. (2010). Correlation 
between folate and vitamin B₁₂ and markers of DNA stability in healthy men: 
preliminary results. Acta biochimica Polonica 57 (3): 339-45 
Moller P, Knudsen LE, Loft Steffen, Wallin H. (2000). The comet assay as a 
rapid Test in Biomonitoring occupational Exposure to DNA damaging Agents 
and Effect of confounding Factors Cancer. Epidemiol Biomarkers Prev 9: 1005-
1015 
91 
 
Moller P, Loft Steffen. (2006). Review Article. Dietary antioxidants and 
beneficial effect on oxidatively damaged DNA. Free Radical Biology & Medicine 
(41): 388-415 
Morita Y, Takahashi H, Kamihata H, Yamamoto Y, Hara K, Iwasaka T. (2001). 
Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases after 
spasm provocation tests in patients with coronary spastic angina. International 
Journal of Cardiology 80: 243 – 250 
Moser B, Szekeres T, Biegelmayer C, Wagner KH, Mišík M, Kundi M, Zakerska 
O, Nersesyan A, Kager  N Zahrl J, Hoelzl C, Ehrlich V, Knasmueller S. (2011).  
Impact of spinach consumption on DNA stability in peripheral lymphocytes and 
on biochemical blood parameters: results of a human intervention trial. 
European journal of nutrition 49 (7): 587-594  
Mukherjee S. (2011). Gilbert Syndrome. URL: 
http://emedicine.medscape.com/article/176822-overview (access date: 
06.10.2011) 
Neuzil J and Stocker. (1994). Free and Albumin-bound Bilirubin Are Efficient 
Co-antioxidants for α-Tocopherol, inhibiting Plasma and Low Density 
Lipoprotein Lipid Peroxidation. The Journal of Biological Chemistry 269 (24): 
16712 – 16719 
Niki E. (2010). Assessment of antioxidant capacity in vitro and in vivo. Free 
radical biology & medicine 49 (4): 503-15 
Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka H-M, Lakka TA, 
Salonen JT. (2004). Uric acid Level as a Risk Factor for Cardiovascular and All-
Cause Mortality in Middle-aged men. Arch Intern Med 164: 1546-51 
Noriega GO, Tomaro ML, del Batlle AMC. (2003). Bilirubin is highly effective in 
preventing invivo δ-aminolevulinic acid-induced oxidative cell damage. 
Biochemica et Biophysica Acta 1638: 173 – 178 
92 
 
Novotný L, Vitek L. (2003). Inverse relationship between serum bilirubin and 
atherosclerosis in men: a meta-analysis of published studies. Experimental 
Biology and Medicine 228: 568 – 571 
Petrides PE. (2007). Häm und Gallenfarbstoffe. In: Löffler G, Petrides PE,  
Heinrich PC (Hrsg.). Biochemie & Pathobiochemie. 8. Auflage. Springer Medizin 
Verlag, Heidelberg: 607 – 630  
Piperakis SM. (2009). Comet assay: A brief history. Cell Biology and Toxicology 
25: 1 – 3 
Rao P, Suzuki R, Mizobuchi S, Yamaguchi T, Sasaguri S. (2006). Bilirubin 
exhibits a novel anti-cancer effect on human adenocarcinoma. Biochemical and 
Biophysical Research Communication 342: 1279 – 1283 
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. (2010). Oxidative stress, 
inflammation, and cancer: How are they linked? Free radical biology & medicine 
49 (11): 1603-1616 
Roberts CK, Sindhu KK. (2009). Oxidative stress and metabolic syndrome. Life 
sciences 84: 705 – 712 
Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E. (2008). Minireview The 
antioxidant properties of serum albumin. FEBS Letters 582: 1783 – 1787 
Ruggiero C, Cherubini A, Ble A, Bos AJG, Maggio M, Dixit VD, Lauretani F, 
Bandinelli S, Senin U, Ferrucci L. (2006). Uric acid and inflammatory markers. 
European heart journal 27 (10): 1174-8 
Schwertner HA, Jackson WG, Tolan G. (1994). Association of low concentration 
of bilirubin with increased risk of coronary artery disease. Clinical Chemistry 
40/1: 18 – 23 
Sedlak TW, Snyder SH. (2004). Bilirubin Benefits: Cellular Protection by a 
Biliverdin Reductase Antioxidant Cycle. Pediatrics 113: 1776 – 1782 
93 
 
Sedlak TW, Saleh M, Higginson DS, Paul B, Juluri KR, Snyder SH. (2009). 
Bilirubin and glutathione have complementary antioxidant and cytoprotective 
roles. Proceedings of the National Academy of Sciences of the United States of 
America 106 (13): 5171-6 
Silverstein A, Silverstein V, Silverstein VB, Silverstein-Nunn L. (2008). DNA. 
Twenty-First Century Books, Minneapolis: 9-12 
Shimoharada K, Inoue S, Nakahara M, Shimizu S, Kang D, Hamasaki N, 
Kinoshita S. (1998). Urine Concentration of Biopyrrins: A New Marker for 
Oxidative Stress in Vivo. Clinical Chemistry 44 (12): 2554 – 2555 
Speit, G. (2004). Sensitivity of the FPG protein towards alkylation damage in the 
comet assay. Toxicology Letters 146 (2): 151-158 
Stocker R, Glaszer AN, Ames BN. (1987). Antioxidant activity of albumin-bound 
bilirubin. Proceedings of the National Academy of Sciences. USA 84: 5918 – 
5922 
Stocker R and Peterhans E. (1989). Synergistic interaction between vitamin E 
and bile pigments bilirubin and biliverdin. Biochimica et Biophysica Acta (BBA) – 
Lipids and Lipid Metabolism 1002 (2): 238 – 244  
Stocker R. (2004). Antioxidant Activities of Bile Pigments. Antioxidants & Redox 
Signaling 6 (5): 841 – 849 
Stopper H, Boullay F, Heidland A, Vienken J, Bahner U. (2001). Comet-assay 
analysis identifies genomic damage in lymphocytes of uremic patients. Am J. 
Kidney Dis 38 (2): 269 -301 
Stoyanova E, Sandoval SB, Zúñiga LA, El-Yamani N, Coll E, Pastor S, Reyes J, 
Andrés E, Ballarin J, Xamena N, Marcos R. (2010). Oxidative DNA damage in 
chronic renal failure patients. 25 (3): 879-85 
Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H, Diem G, Pfeiffer 
K, Ulmer H. (2008). Serum Uric Acid and Risk of Cardiovascular Mortality: A 
94 
 
Prospective Long-Term Study of 83 683 Austrian Men. Clinical Chemistry 54 
(2): 273 – 284 
Temme EH, Zhang J, Schouten EG, Kesteloot H. (2001). Serum bilirubin and 
10-year mortality risk in Belgian population. Cancer Causes Control 12 (10): 
887 – 894 
Thompson RPH. (2003). Jaundice. In: Warrel DA, Cox TM, Firth JD, Benz EJ. 
Oxford Textbook of Medicine. Volume 2. Fourth Edition. Oxford University 
Press: 708 – 713 
Tomaro ML, del C Battle AM. (2002). Bilirubin: its role in cytoprotection against 
oxidative stress. The International Journal of Biochemistry & Cell Biology 34: 
216-220 
Valavanidis A, Vlachogianni T, Fiotakis C. (2009). 8-hydroxy-2’-
desoxyguanosine (8-OHdG): A critical Biomarker of Oxidative Stress and 
Carcinogenesis. Journal of Environmental Science and Health Part C 27: 120 – 
139 
Valko M, Leibfritz D, Moncol  J, Cronin MTD, Mazur M, Telser J. (2006). Review 
Free radicals and antioxidants in normal physiological functions and human 
disease. The International Journal of Biochemistry & Cell Biology 39: 44 – 84 
Vitek L, Jirsa M, Brodanová M, Kaláb M, Marecek Z, Danzig V, Novotný L, Kotal 
P. (2002). Gilbert syndrome and ischemic heart disease: a protective effect of 
elevated bilirubin levels. Atherosclerosis 160: 449 – 456 
Vitek L, Kráslová I, Muchová L, Novotný L, Yamaguchi T. (2007). Urinary 
excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. 
Journal of Gastroenterology and Hepatology 22: 841 – 845 
Vitek L, Ostrow JD. (2009). Bilirubin Chemistry and Metabolsim; Harmful and 
protective aspects. Current Pharmaceutical  Design 15: 2869-2883 
95 
 
Wagner A, Jahreis G. (2004). Nachweis von DNA-Schäden mittels Analyse von 
oxidierten Nukleosiden und deren Anwendung als Biomarker. Ernährungs-
Umschau 51 (5): 178 – 185  
Weinstein SJ, Mackrain K, Stolzenberg-Solomon RZ, Selhub J, Virtamo J, 
Albanes D. (2009). Serum creatinine and prostate cancer risk in a prospective 
study. Cancer epidemiology, biomarkers & prevention: a publication of the 
American Association for Cancer Research, cosponsored by the American 
Society of Preventive Oncology 18 (10): 2643-9 
Wu LL, Chiou CC, Chang PY, Wu JT. (2004). Review Urinary 8-OHdG: a 
marker of oxidative stress to DNA and a risk factor for cancer, arthersclerosis 
and diabetes. Clinica Chimica Acta 339: 1 – 9  
Yesilova Z, Serdar M, Ercin CN, Gunay A, Kilciler G, Hasimi A, Uygun A, Kurt I, 
Erbil MK, Dagalp K. (2008). Decreased oxidation susceptibility of plasma 
low density lipoproteins in patients with Gilbert’s syndrome. Journal of 
Gastroenterology and Hepatology 23: 1556 – 1560 
Zijno A, Andreoli C, Leopardi P, Marcon F, Rossi S, Caiola S, Verdina A, Galati 
R, Cafolla A, Crebelli R. (2003). Folate status, metabolic genotype, and 
biomarkers of genotoxicity in healthy subjects. Carcinogenesis 24(6): 1097-103 
Zucker SD, Horn PS, Sherman KE. (2004). Serum bilirubin levels in the U.S. 
population: gender effect and inverse correlation with colorectal cancer. 
Hepatology. 40 (4): 827 – 835 
URL: 
http://carmonet.50webs.com/CNS/phenobarb.html (access date 16.06.2011) 
 
  
96 
 
 
  
97 
 
9. Appendix 
a. Comparison of DNA damage in Gilbert’s syndrome and 
Control 
a.1. Differences in GS and Control 
Table: % DNA in tail in GS and control (all test subjects) 
 Gilbert’s syndrome Control pValue 
Number 45 37  
% DNA in tail Lysis 5.3 ± 1.35 5.0 ± 1.18 0.252 
% DNA in tail FPG 5.3 ± 3.13 4.6 ± 2.32 0.231 
% DNA in tail ENDO III 2.1 ± 1.17 2.5 ± 1.38 0.245 
a.2. Differences in GS and Control stratified for gender 
Table: % DNA in tail in GS and control (men and women) 
 Gilbert’s syndrome Control pValue 
Men    
Number 35 22  
% DNA in tail Lysis 5.5 ±1.27 5.1 ± 1.23 0.245 
% DNA in tail FPG 5.4 ± 3.28 5.0 ± 2.46 0.588 
% DNA in tail ENDO III 2.2 ± 1.05 2.7 ± 1.38 0.157 
Women    
Number 10 15  
% DNA in tail Lysis 4.5 ± 1.35 4.7 ± 1.12 0.626 
% DNA in tail FPG 4.9 ± 2.65 3.9 ± 2.03 0.326 
% DNA in tail ENDO III 2.0 ± 1.54 1.38 ± 1.38 0.749 
a.3. Differences in GS and Control stratified for age  
Table: % DNA in tail in GS and control (< 30 years and ≥ 30 years) 
 Gilbert’s syndrome Control pValue 
< 30    
Number 26 23  
% DNA in tail Lysis 5.2 ± 1.35 4.8 ± 1.14   0.217 
% DNA in tail FPG 5.9 ± 3.74 5.1 ± 2.33 0.353 
% DNA in tail ENDO III 2.2 ± 1.07 2.5 ± 1.07 0.360 
≥ 30    
Number 19 14  
% DNA in tail Lysis 5.4 ± 1.37 5.3 ± 1.21 0.831 
% DNA in tail FPG 4.5 ± 1.84 3.7 ± 2.1 0.267 
% DNA in tail ENDO III 2.1 ± 1.31 3.4 ± 1.49 0.540 
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a.4. Differences in GS and Control stratified for age and gender 
Table: % DNA in tail in GS and control (stratified for age and gender) 
 Gilbert’s syndrome Control pValue 
Men < 30    
Number 22 14  
% DNA in tail Lysis 5.4 ± 1.31 5.0 ± 1.13 0.300 
% DNA in tail FPG 6.1 ± 3.82 5.7 ± 2.26 0.635 
% DNA in tail ENDO III 2.4 ± 1.02 2.8 ± 1.27 0.297 
Men ≥ 30    
Number 13 8  
% DNA in tail Lysis 5.7 ± 1.23 5.4 ± 1.42 0.598 
% DNA in tail FPG 4.25 ± 1.59 3.8 ± 2.49 0.648 
% DNA in tail ENDO III 2.0 ± 1.09 2.5 ± 1.62 0.381 
Women < 30    
Number 4 9  
% DNA in tail Lysis 4.1 ± 1.04 4.4 ± 1.14 0.606 
% DNA in tail FPG 4.5 ± 3.38 4.1 ± 2.25 0.815 
% DNA in tail ENDO III 1.5 ± 1.14 2.17 ± 1.46 0.432 
Women ≥ 30    
Number 6 6  
% DNA in tail Lysis 4.8 ± 1.55 5.2 ± 0.98 0.575 
% DNA in tail FPG 5.1 ± 2.36 3.6 ± 1.78 0.241 
% DNA in tail ENDO III 2.3 ± 1.78 2.2 ± 1.37 0.906 
 
b. Comparison of DNA damage in bilirubin tertiles  
b.1. Differences in bilirubin tertiles  
Table: % DNA in tail in bilirubin tertiles (all test subjects) 
 Tertile 1: 
0.24-0.65 mg/dl 
Tertile 2: 
0.66 -1.21 mg/dl 
Tertile 3: 
1.22 -4.3  
mg/dl 
pValue 
Number 31 34 33  
% DNA in tail Lysis 4.9 ± 1.21 5.3 ± 1.14 5.1 ± 1.33 0.328 
% DNA in tail FPG 4.7 ± 2.42 5.1 ± 3.08 4.7 ± 2.81 0.833 
% DNA in tail ENDO III 2.3 ± 1.29 1.9 ± 1.32 2.2 ± 1.12 0.410 
 
 
 
 
99 
 
b.2. Differences in bilirubin tertiles stratified for gender  
Table: % DNA in tail in bilirubin tertiles (men and women) 
 Tertile 1: 
0.24-0.65 
mg/dl 
Tertile 2: 
0.66 -1.21 
mg/dl 
Tertile 3: 
1.22 -4.3 
mg/dl 
pValue 
Men     
Number 16 26 27  
% DNA in tail Lysis 5.3 ± 1.31 5.5 ± 1.12 5.3 ± 1.26 0.834 
% DNA in tail FPG 5.2 ± 2.76 5.2 ± 3.13 4.9 ± 2.95 0.903 
% DNA in tail ENDO III 2.6 ± 1.33 2.1 ± 1.33 2.2 ± 0.98 0.397 
Women     
Number 15 8 6  
% DNA in tail Lysis 4.5 ± 0.95 4.9 ± 1.19 4.5 ± 1.58 0.622 
% DNA in tail FPG 4.2 ± 1.99 4.8 ± 3.07 4.3 ± 2.25 0.832 
% DNA in tail ENDO III 2.1 ± 1.23 1.5 ± 1.26 2.6 ±1.68 0.337 
b.3. Differences in bilirubin tertiles stratified for age 
Table: % DNA in tail in bilirubin tertiles (< 30 years and ≥ 30 years) 
 Tertile 1: 
0.24-0.65 
mg/dl 
Tertile 2: 
0.66 -1.21 
mg/dl 
Tertile 3: 
1.22 -4.3 
mg/dl 
pValue 
< 30     
Number 23 21 17  
% DNA in tail Lysis 4.6 ± 1.04 5.6 ± 1.10 4.8 ± 1.29 0.016
% DNA in tail FPG 5.0 ± 2.34 5.6 ± 3.40 5.0 ± 3.54 0.781 
% DNA in tail ENDO III 2.5 ± 1.33 1.9 ± 1.24 2.2 ± 0.99 0.239 
≥ 30     
Number 8 13 16  
% DNA in tail Lysis 5.6 ± 1.45 4.9 ± 1.13 5.5 ± 1.31 0.389 
% DNA in tail FPG 3.9 ± 2.66 4.3 ± 2.35 4.5 ± 1.83 0.854 
% DNA in tail ENDO III 1.9 ± 1.09 2.1 ± 1.50 2.3 ± 1.26 0.767 
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b.4. Differences in bilirubin tertiles stratified for age and gender  
Table: % DNA in tail in bilirubin tertiles (stratfied for age and gender) 
 Tertile 1: 
0.24-0.65 
mg/dl 
Tertile 2: 
0.66 -1.21 
mg/dl 
Tertile 3: 
1.22 -4.3 
mg/dl 
pValue 
Men < 30     
Number 12 17 15  
% DNA in tail Lysis 5.2 ± 1.6 5.6 ± 1.18 4.99 ± 1.22 0.310 
% DNA in tail FPG 5.6 ± 2.45 5.6 ± 3.41 5.3 ± 3.69 0.943 
% DNA in tail ENDO III 2.8 ± 1.38 2.0 ± 1.26 2.2 ± 0.94 0.266 
Men ≥ 30     
Number 4 9 12  
% DNA in tail Lysis 5.6 ± 2.09 5.2 ± 1.02 5.7 ± 1.26 0.726 
% DNA in tail FPG 3.9 ± 3.59 4.3 ± 2.47 4.3 ± 1.63 0.946 
% DNA in tail ENDO III 2.0 ± 1.18 2.2 ± 1.51 2.1 ± 1.05 0.970 
Women < 30     
Number 11 4 2  
% DNA in tail Lysis 4.0 ± 0.63 5.6 ± 0.79 3.3 ± 0.83 0.002 
% DNA in tail FPG 4.3 ± 2.11 5.4 ± 3.88 3.1 ± 0.99 0.560 
% DNA in tail ENDO III 2.2 ± 1.28 1.2 ± 1.00 1.7 ± 1.69 0.421 
Women ≥ 30     
Number 4 4 4  
% DNA in tail Lysis 5.6 ± 0.71 4.3 ± 1.29 5.1 ± 1.58 0.380 
% DNA in tail FPG 3.93 ± 1.89 4.2 ± 2.43 4.8 ± 2.60 0.855 
% DNA in tail ENDO III 1.7 ± 1.17 1.8 ± 1.74 3.0 ± 1.73 0.486 
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c. Correlations 
c.1. Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG  
Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (all test subjects) 
All test 
subjects 
 Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.387** 
0.000 
1 
 
     
ENDO III r 
p 
0.183 
0.077 
0.289**
0.005 
1 
 
    
BMI r 
p 
0.175 
0.085 
-0.042 
0.678 
-0.003 
0.975 
1 
 
   
LDL r 
p 
-0.079 
0.439 
-0.160 
0.116 
0.002 
0.984 
0.363**
0.000 
1   
HDL r 
p 
-0.164 
0.106 
0.020 
0.848 
0.076 
0.468 
-0.240*
0.016 
-0.063 
0.535 
1  
TG r 
p 
0.025 
0.808 
-0.035 
0.734 
-0.013 
0.902 
0.364**
0.000 
0.248*
0.013 
-0.133 
0.186 
1 
 
Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (men) 
Men   Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.362** 
0.002 
1 
 
     
ENDO III r 
p 
0.269* 
0.028 
0.272*
0.026 
1 
 
    
BMI r 
p 
0.277* 
0.021 
-0.048 
0.695 
0.073 
0.559 
1 
 
   
LDL r 
p 
-0.074 
0.547 
-0.210 
0.083 
-0.060 
0.627 
0.348**
0.003 
1   
HDL r 
p 
-0.137 
0.261 
-0.016 
0.893 
0.009 
0.943 
-0.177 
0.143 
-0.030 
0.808 
1  
TG r 
p 
0.093 
0.445 
-0.042 
0.732 
0.000 
0.997 
0.372**
0.002 
0.290*
0.015 
-0.277* 
0.020 
1 
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Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (women) 
Women  Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.376* 
0.044 
1 
 
     
ENDO III r 
p 
-0.069 
0.732 
0.331 
0.091 
1 
 
    
BMI r 
p 
-0.080 
0.680 
-0.059 
0.760 
-0.187 
0.351 
1 
 
   
LDL r 
p 
-0.245 
0.200 
-0.029 
0.880 
0.148 
0.461 
0.401*
0.028 
1   
HDL r 
p 
0.081 
0.677 
0.268 
0.161 
0.301 
0.128 
-0.291 
0.119 
0.015 
0.938 
1  
TG r 
p 
-0.069 
0.721 
0.015 
0.939 
-0.034 
0.867 
0.375*
0.041 
0.169 
0.372 
-0.021 
0.911 
1 
 
Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (< 30 years) 
<30 years  Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.382** 
0.002 
1 
 
     
ENDO III r 
p 
0.165 
0.212 
0.374** 
0.003 
1 
 
    
BMI r 
p 
0.141 
0.278 
0.035 
0.788 
0.179 
0.175 
1 
 
   
LDL r 
p 
-0.119 
0.361 
-0.043 
0.740 
-0.012 
0.931 
0.217 
0.092 
1   
HDL r 
p 
-0.229 
0.076 
-0.003 
0.981 
0.079 
0.551 
-0.138 
0.289 
-0.182 
0.160 
1  
TG r 
p 
-0.032 
0.807 
-0.100 
0.441 
-0.011 
0.933 
0.368**
0.004 
0.083 
0.524 
-0.040 
0.759 
1 
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Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (≥ 30 years) 
≥ 30 years  Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.485** 
0.002 
1 
 
     
ENDO III r 
p 
0.220 
0.204 
0.116 
0.505 
1 
 
    
BMI r 
p 
0.151 
0.371 
-0.042 
0.806 
-0.271 
0.115 
1 
 
   
LDL r 
p 
-0.102 
0.547 
-0.303 
0.068 
0.028 
0.874 
-0.429**
0.006 
1   
HDL r 
p 
-0.116 
0.494 
0.133 
0.433 
0.074 
0.673 
-0.471**
0.002 
0.010 
0.951 
1  
TG r 
p 
0.093 
0.584 
0.120 
0.481 
-0.015 
0.931 
0.361*
0.024 
0.442** 
0.005 
-0.267 
0.101 
1 
 
Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (men < 30 years) 
Men < 30 years   Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.382* 
0.011 
1 
 
     
ENDO III r 
p 
0.329* 
0.033 
0.378*
0.014 
1 
 
    
BMI r 
p 
0.195 
0.205 
-0.041 
0.792 
0.195 
0.215 
1 
 
   
LDL r 
p 
-0.093 
0.550 
-0.097 
0.530 
-0.176 
0.264 
0.252 
0.099 
1   
HDL r 
p 
-0.033 
0.830 
0.103 
0.506 
-0.017 
0.916 
-0.116 
0.453 
-0.240 
0.117 
1  
TG r 
p 
0.029 
0.853 
-0.152 
0.324 
0.036 
0.822 
0.366*
0.015 
0.195 
0.205 
-0.293 
0.053 
1 
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Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (men ≥ 30 years) 
Men ≥ 30 years   Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.431* 
0.031 
1 
 
     
ENDO III r 
p 
0.191 
0.361 
0.000 
1.000 
1 
 
    
BMI r 
p 
0.416* 
0.039 
0.282 
0.172 
-0.065 
0.758 
1 
 
   
LDL  r 
p 
-0.113 
0.591 
-0.318 
0.122 
0.178 
0.395 
0.263 
0.195 
1   
HDL r 
p 
-0.338 
0.099 
-0.305 
0.139 
0.069 
0.743 
-0.417*
0.034 
0.291 
0.149 
1  
TG r 
p 
0.149 
0.476 
0.249 
0.230 
-0.025 
0.907 
0.326 
0.104 
0.332 
0.097 
-0.291 
0.149 
1 
 
 
 
Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (women < 30 years) 
Women <  30 years   Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.234 
0.365 
1 
 
     
ENDO III r 
p 
-0.499* 
0.041 
0.323 
0.206 
1 
 
    
BMI r 
p 
0.007 
0.980 
0.305 
0.234 
0.134 
0.608 
1 
 
   
LDL r 
p 
-0.336 
0.187 
0.176 
0.500 
0.521*
0.032 
0.097 
0.711 
1   
HDL  r 
p 
-0.319 
0.212 
-0.061 
0.817 
0.452 
0.069 
-0.214 
0.409 
-0.043 
0.869 
1  
TG r 
p 
0.093 
0.722 
0.133 
0.610 
-0.018 
0.944 
0.410 
0.102 
-0.171 
0.511 
0.147 
0.574 
1 
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Table: Correlation between lysis, FPG, ENDO III, BMI, LDL, HDL and TG (women ≥ 30 years) 
Women ≥ 30 years   Lysis FPG ENDO III BMI LDL HDL TG 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.645* 
0.024 
1 
 
     
ENDO III r 
p 
0.318 
0.370 
0.366 
0.298 
1 
 
    
BMI r 
p 
-0.241 
0.451 
-0.452 
0.140 
-0.538 
0.109 
1 
 
   
LDL r 
p 
-0.245 
0.442 
-0.286 
0.367 
-0.275 
0.442 
0.601*
0.030 
1   
HDL r 
p 
0.352 
0.262 
0.751**
0.005 
0.046 
0.900 
-0.406 
0.168 
0.034 
0.913 
1  
TG r 
p 
-0.174 
0.589 
-0.289 
0.362 
0.074 
0.839 
0.482 
0.095 
0.776** 
0.002 
-0.190 
0.534 
1 
 
c.2. Correlations between lysis, FPG, ENDO III, creatinine, uric acid, 
albumin 
Table: Correlation between lysis, FPG, ENDO III,  creatinine, uric acid and albumin ( all test subjects) 
All test subjects  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
    
FPG r 
p 
0.378** 
0.000 
1 
 
    
ENDO III r 
p 
0.183 
0.077 
0.289**
0.005 
1 
 
   
Creatinine r 
p 
0.298** 
0.003 
0.164 
0.107 
0.086 
0.413 
1 
 
  
Uric acid r 
p 
0.426** 
0.000 
0.213*
0.035 
0.092 
0.377 
0.537**
0.000 
1  
Albumin r 
p 
-0.137 
0.178 
0.037 
0.716 
0.110 
0.290 
0.302**
0.002 
0.235* 
0.019 
1 
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Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin (men) 
Men  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.362**
0.002 
1 
 
    
ENDO III r 
p 
0.269*
0.028 
0.272* 
0.026 
1 
 
   
Creatinine r 
p 
0.106 
0.385 
0.076 
0.532 
0.099 
0.428 
1 
 
  
Uric acid r 
p 
0.411**
0.000 
0.1867 
0.125 
0.135 
0.275 
0.221 
0.066 
1  
Albumin r 
p 
-0.244*
0.044 
0.003 
0.980 
0.008 
0.950 
0.176 
0.144 
-0.015 
0.900 
1 
 
Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin (women) 
Women  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.376*
0.044 
1 
 
    
ENDO III r 
p 
-0.069 
0.732 
0.331 
0.091 
1 
 
   
Creatinine r 
p 
0.308 
0.104 
0.336 
0.075 
-0.102 
0.613 
1 
 
  
Uric acid r 
p 
0.108 
0.578 
0.184 
0.338 
-0.136 
0.498 
0.042 
0.824 
1  
Albumin r 
p 
-0.387*
0.038 
-0.038 
0.846 
0.237 
0.234 
-0.332 
0.073 
0.005 
0.980 
1 
 
Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin (< 30 years) 
< 30 years  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.382**
0.002 
1 
 
    
ENDO III r 
p 
0.165 
0.212 
0.374** 
0.003 
1 
 
   
Creatinine r 
p 
0.362**
0.004 
0.218 
0.092 
0.108 
0.414 
1 
 
  
Uric acid r 
p 
0.533**
0.000 
0.245 
0.057 
0.215 
0.102 
0.632**
0.000 
1  
Albumin r 
p 
-0.072 
0.579 
0.028 
0.828 
0.141 
0.287 
0.385**
0.002 
0.302*
0.018 
1 
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Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin (≥ 30years) 
≥ 30 years  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
    
FPG r 
p 
0.485** 
0.002 
1 
 
    
ENDO III r 
p 
0.220 
0.204 
0.116 
0.505 
1 
 
   
Creatinine r 
p 
0.211 
0.210 
0.035 
0.835 
0.049 
0.782 
1 
 
  
Uric acid r 
p 
0.273 
0.102 
0.119 
0.482 
-0.139 
0.427 
0.371*
0.020 
1  
Albumin r 
p 
-0.158 
0.351 
-0.116 
0.494 
0.061 
0.727 
0.165 
0.315 
0.096 
0.561 
1 
 
Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin (women < 30 years) 
Women < 30 years   Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
    
FPG r 
p 
0.234 
0.365 
1 
 
    
ENDO III r 
p 
-0.499* 
0.041 
0.323 
0.206 
1 
 
   
Creatinine r 
p 
0.231 
0.372 
0.313 
0.221 
-0.277 
0.282 
1 
 
  
Uric acid r 
p 
0.293 
0.254 
0.214 
0.410 
-0.013 
0.960 
0.160 
0.539 
1  
Albumin r 
p 
-0.565* 
0.018 
-0.021 
0.935 
0.382 
0.130 
-0.228 
0.378 
-0.384 
0.128 
1 
 
 
Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin ( women ≥ 30 years) 
Women ≥ 30 years  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
    
FPG R 
p 
0.645* 
0.024 
1 
 
    
ENDO III R 
p 
0.318 
0.370 
0.366 
0.298 
1 
 
   
Creatinine R 
p 
0.424 
0.169 
0.377 
0.226 
0.106 
0.771 
1 
 
  
Uric acid R 
p 
-0.131 
0.685 
0.192 
0.551 
-0.348 
0.324 
-0.034 
0.913 
1  
Albumin R 
p 
-0.153 
0.636 
-0.078 
0.810 
-0.024 
0.947 
-0.514 
0.073 
0.453 
0.120 
1 
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Table: Correlation between lysis, FPG, ENDO III, creatinine, uric acid and albumin ( men < 30 years) 
Men < 30 years  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis r 
p 
1 
 
     
FPG r 
p 
0.382*
0.011 
1 
 
    
ENDO III R 
p 
0.329*
0.033 
0.378* 
0.014 
1 
 
   
Creatinine R 
p 
0.149 
0.334 
0.121 
0.434 
0.092 
0.563 
1 
 
  
Uric acid R 
p 
0.444**
0.003 
0.184 
0.233 
0.211 
0.180 
0.352*
0.019 
1  
Albumin R 
p 
-0.245 
0.110 
-0.102 
0.509 
-0.152 
0.337 
0.165 
0.283 
0.047 
0.763 
1 
 
Table: Correlation between lysis,FPG, ENDO III, creatinine, uric acid and albumin ( men ≥ 30 years) 
Men ≥ 30 years  Lysis FPG ENDO III Creatinine Uric acid Albumin 
Lysis R 
p 
1 
 
     
FPG R 
p 
0.431*
0.031 
1 
 
    
ENDO III R 
p 
0.191 
0.361 
0.000 
1.000 
1 
 
   
Creatinine R 
p 
0.028 
0.893 
-0.029 
0.892 
0.120 
0.567 
1 
 
  
Uric acid R 
p 
0.389 
0.055 
0.132 
0.529 
-0.024 
0.911 
-0.039 
0.850 
1  
Albumin R 
p 
-0.233 
0.263 
-0.132 
0.530 
0.112 
0.593 
0.233 
0.252 
-0.243 
0.231 
1 
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c.3. Correlations between lysis, FPG, ENDO III, age, UCB, iron, vitamin C 
and glutathione 
Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion ( all test subjects) 
All test 
subjects 
 Lysis FPG ENDO 
III 
Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.387** 
0.000 
1 
 
      
ENDO III r 
p 
0.183 
0.077 
0.289**
0.005 
1 
 
     
Age r 
p 
0.077 
0.452 
-0.090 
0.378 
-0.070 
0.506 
1 
 
    
UCB r 
p 
0.055 
0.592 
0.094 
0.356 
-0.050 
0.634 
0.125 
0.216 
1    
Iron r 
p 
-0.027 
0.794 
-0.034 
0.738 
-0.061 
0.562 
-0.093 
0.360 
0.480**
0.000 
1   
Vitamin C r 
p 
0.057 
0.578 
0.099 
0.334 
0.111 
0.286 
-0.113 
0.263 
-0.085 
0.403 
0.151 
0.135 
1  
Glutathion r 
p 
0.225* 
0.026 
0.031 
0.764 
0.105 
0.313 
0.149 
0.140 
-0.051 
0.618 
-0.072 
0.481 
0.102 
0.314 
1 
 
Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathione (men) 
Men  Lysis FPG ENDO III Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.362** 
0.002 
1 
 
      
ENDO III r 
p 
0.269* 
0.028 
0.272*
0.026 
1 
 
     
Age r 
p 
0.005 
0.967 
-0.131 
0.85 
-0.138 
0.266 
1 
 
    
UCB r 
p 
-0.013 
0.913 
0.083 
0.500 
-0.099 
0.427 
0.153 
0.207 
1    
Iron r 
p 
-0.131 
0.288 
-0.126 
0.305 
-0.210 
0.090 
-0.111 
0.364 
0.457**
0.000 
1   
Vitamin C r 
p 
0.118 
0.335 
0.127 
0.298 
0.030 
0.810 
-0.107 
0.380 
-0.151 
0.212 
0.080 
0.512 
1  
Glutathion r 
p 
0.309** 
0.010 
0.107 
0.380 
0.065 
0.604 
0.065 
0.591 
-0.019 
0.875 
-0.118 
0.334 
0.086 
0.478 
1 
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Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (women) 
Women  Lysis FPG ENDO 
III 
Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
       
FPG r 
p 
0.376* 
0.044 
1 
 
      
ENDO III r 
p 
-0.069 
0.732 
0.331 
0.091 
1 
 
     
Age r 
p 
0.326 
0.084 
0.051 
0.793 
0.083 
0.680 
1 
 
    
UCB r 
p 
-0.050 
0.795 
0.002 
0.991 
0.021 
0.916 
0.142 
0.453 
1    
Iron r 
p 
-0.061 
0.753 
0.113 
0.559 
0.186 
0.353 
0.006 
0.973 
0.400 
0.029 
1   
Vitamin C r 
p 
0.010 
0.960 
0.068 
0.728 
0.301 
0.127 
-0.146 
0.443 
0.192 
0.310 
0.384*
0.036 
1  
Glutathion r 
p 
0.315 
0.096 
-0.081 
0.676 
0.250 
0.208 
0.319 
0.092 
0.093 
0.631 
0.212 
0.270 
0.093 
0.633 
1 
 
Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (< 30 years) 
< 30 years  Lysis FPG ENDO 
III 
Age UCB Iron Vitamin 
C 
Glutathion 
Lysis r 
p 
1 
 
       
FPG r 
p 
0.382** 
0.002 
1 
 
      
ENDO III r 
p 
0.165 
0.212 
0.374** 
0.003 
1 
 
     
Age r 
p 
-0.014 
0.914 
-0.067 
0.607 
-0.022 
0.867 
1 
 
    
UCB r 
p 
-0.020 
0.878 
0.148 
0.255 
-0.111 
0.403 
0.124 
0.341 
1    
Iron r 
p 
-0.002 
0.986 
-0.060 
0.648 
-0.148 
0.263 
0.108 
0.407 
0.541**
0.000 
1   
Vitamin C r 
p 
0.185 
0.153 
0.138 
0.290 
-0.031 
0.818 
0.077 
0.553 
0.047 
0.720 
0.195 
0.133 
1  
Glutathion r 
p 
0.331** 
0.009 
0.199 
0.124 
0.090 
0.499 
-0.273* 
0.033 
0.083 
0.526 
-0.146 
0.260 
0.078 
0.548 
1 
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Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (≥ 30 years) 
≥ 30 years  Lysis FPG ENDO 
III 
Age UCB Iron Vitamin 
C 
Glutathion 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.485** 
0.002 
1 
 
      
ENDO III r 
p 
0.220 
0.204 
0.116 
0.505 
1 
 
     
Age r 
p 
-0.044 
0.796 
0.178 
0.293 
-0.150 
0.391 
1 
 
    
UCB r 
p 
0.124 
0.466 
0.061 
0.720 
0.033 
0.852 
0.083 
0.616 
1    
Iron r 
p 
-0.050 
0.773 
-0.014 
0.936 
0.129 
0.467 
-0.078 
0.640 
0.387*
0.016 
1   
Vitamin C r 
p 
-0.096 
0.574 
-0.026 
0.879 
0.329 
0.054 
-0.172 
0.295 
-0.239 
0.142 
0.054 
0.747 
1  
Glutathion r 
p 
0.014 
0.934 
-0.085 
0.615 
0.159 
0.362 
-0.337*
0.039 
-0.329*
0.044 
0.192 
0.255 
0.235 
0.155 
1 
 
Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (women < 30 years) 
Women 
< 30 years 
 Lysis FPG ENDO 
III 
Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.234 
0.365 
1 
 
      
ENDO III r 
p 
-0.499* 
0.041 
0.323 
0.206 
1 
 
     
Age r 
p 
-0.014 
0.958 
-0.393 
0.119 
0.010 
0.968 
1 
 
    
UCB r 
p 
-0.098 
0.710 
-0.060 
0.820 
-0.179 
0.493 
0.131 
0.617 
1    
Iron r 
p 
-0.025 
0.926 
0.110 
0.675 
-0.100 
0.704 
-0.048 
0.855 
0.516*
0.034 
1   
Vitamin C r 
p 
0.018 
0.946 
-0.037 
0.888 
0.066 
0.800 
0.106 
0.687 
0.327 
0.200 
0.585* 
0.014 
1  
Glutathion r 
p 
0.087 
0.741 
-0.143 
0.584 
0.145 
0.578 
-0.081 
0.756 
0.164 
0.529 
-0.063 
0.811 
0.038 
0.884 
1 
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Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (women ≥ 30 years) 
Women 
≥ 30 years 
 Lysis FPG ENDO 
III 
Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
       
FPG r 
p 
0.645* 
0.024 
1 
 
      
ENDO III r 
p 
0.318 
0.370 
0.366 
0.298 
1 
 
     
Age r 
p 
0.195 
0.544 
0.394 
0.205 
-0.055 
0.881 
1 
 
    
UCB r 
p 
-0.136 
0.674 
0.111 
0.732 
0.206 
0.568 
-0.037 
0.906 
1    
Iron r 
p 
-0.156 
0.629 
0.126 
0.696 
0.567 
0.087 
-0.062 
0.841 
0.260 
0.390 
1   
Vitamin C r 
p 
0.135 
0.677 
0.212 
0.508 
0.654*
0.040 
-0.039 
0.900 
0.114 
0.711 
0.188 
0.538 
1  
Glutathion r 
p 
0.262 
0.411 
-0.016 
0.960 
0.297 
0.405 
-0.433 
0.160 
-0.176 
0.583 
0.459 
0.133 
0.432 
0.161 
1 
 
Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (men < 30 years) 
Men 
< 30 years 
 Lysis FPG ENDO Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
       
FPG r 
p 
0.382* 
0.011 
1 
 
      
ENDO III r 
p 
0.329* 
0.033 
0.378* 
0.014 
1 
 
     
Age r 
p 
-0.052 
0.737 
-0.004 
0.982 
-0.054 
0.736 
1 
 
    
UCB r 
p 
-0.147 
0.341 
0.142 
0.356 
-0.150 
0.344 
0.104 
0.503 
1    
Iron r 
p 
-0.156 
0.313 
-0.170 
0.269 
-0.236 
0.133 
0.128 
0.406 
0.497**
0.001 
1   
Vitamin C r 
p 
0.354* 
0.018 
0.236 
0.123 
-0.040 
0.801 
0.085 
0.583 
0.029 
0.852 
0.138 
0.372 
1  
Glutathion r 
p 
0.488* 
0.001 
0.306* 
0.043 
0.103 
0.517 
-0.313*
0.038 
0.116 
0.453 
-0.128 
0.409 
0.069 
0.658 
1 
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Table: Correlation between lysis, FPG, ENDO III, age, UCB, iron, vitamin C and glutathion (men ≥ 30 years) 
Men 
≥ 30 years 
 Lysis FPG ENDO 
III 
Age UCB Iron Vitamin C Glutathion 
Lysis r 
p 
1 
 
      
FPG r 
p 
0.431* 
0.031 
1 
 
      
ENDO III r 
p 
0.191 
0.361 
0.000 
1.000 
1 
 
     
Age r 
p 
-0.110 
0.599 
0.100 
0.634 
-0.199 
0.339 
1 
 
    
UCB r 
p 
0.147 
0.484 
0.058 
0.785 
-0.007 
0.974 
0.141 
0.491 
1    
Iron r 
p 
-0.044 
0.837 
-0.109 
0.613 
-0.191 
0.372 
-0.068 
0.748 
0.442*
0.027 
1   
Vitamin C r 
p 
-0.230 
0.270 
-0.157 
0.455 
0.139 
0.508 
-0.240 
0.237 
-0.393*
0.047 
-0.076 
0.717 
1  
Glutathion r 
p 
-0.007 
0.973 
-0.144 
0.493 
0.071 
0.736 
-0.371 
0.062 
-0.311 
0.122 
0110 
0.601 
0.155 
0.451 
1 
 
 
 
 
 
 
 
 
  
114 
 
 
  
115 
 
10. Curriculum vitae 
Personal Information 
Name: Nadja Antl     
Email: nadja.antl@hotmail.com  
Date of Birth: April 24th, 1986   
Citizenship: Austria 
 
Education 
Since 10/2005 Study of Nutritional Sciences 
 Faculty of Life Sciences, University of Vienna 
 Title of Diploma thesis:  
 “Effects of moderate hyperbilirubinemia on DNA damage” 
 Supervisor: Ao. Univ.-Prof. Dr. Karl-Heinz Wagner 
2002-2005 Diploma of the International Baccalauréate Organization,  
 International School of Berne 
1997-2002 High School, European School Brussels 
1995-1997 Primary School, Munich 
1993-1995 Primary School, Vienna 
1992-1993 Primary School, Innsbruck 
 
Research activities abroad 
02/2011-06/2011 Research visit at the working group of    
 Assistant Professor Ali Moazzami 
 Swedish University of Agricultural Sciences 
        Department of Food Science 
 Division of Plant products, Uppsala (Sweden) 
 
116 
 
 
Work Experience 
07/2011 Internship at Children’s University, Vienna 
12/2010 Internship at institution for food safety  
 (Municipal Department 38) 
  Division of microbiology, Vienna 
09/2009 Internship at a food production company  
 Staud’s, Vienna 
07/2009 Internship at an certified organic farm 
 ‘Roots and Greens Farm’, British Columbia, Canada 
07/2008-09/2008 Internship at a food production company Agrana, 
 SectionFruit products, Division quality control,  
 Lower Austria 
04/2008 Internship at the University of Vienna, Department of  
 Nutritional Sciences 
 
Professional Qualifications 
 PC: MS Office, SPSS, SIMCA 
 Languages: German, English, French, Spanish, Swedish 
 
Further Interests 
Winter sports, swimming, traveling, reading 
 
  
117 
 
Erklärung zur gemeinsamen Bearbeitung eines Themas 
 
Gemäß dem Universitätsgesetz §81(Abs. 3 UG) wurden die Diplomarbeiten mit 
dem Titel  
„Evaluation of DNA Damage in Gilbert’s Syndrome Subjects in H2O2-treated 
and untreated PBMCs“ 
und dem zweiten Titel 
“Effects of moderate hyperbilirubinemia on DNA damage“ 
von Barbara Rittmannsberger und Nadja Antl im Rahmen einer Fall-Kontroll-
Studie am Institut für Ernährungswissenschaften unter der Betreuung von Herrn 
Ao. Univ.-Prof. Dr. Karl-Heinz Wagner und Frau Mag. Marlies Wallner an der 
Universität Wien gemeinsam verfasst.  
Im Inhaltsverzeichnis dieser Arbeit sind die Teile der jeweiligen Verfasserin 
genau zugeordnet.  
 
 
 
_________________________      __________________________ 
Unterschrift             Unterschrift  
Barbara Rittmannsberger (19.08.1984)         Nadja Antl (24.04.1986) 
 
Wien, Oktober 2011 
